Skip to content
Calculator

Peptide pipeline tracker: new and coming peptide drugs

This page follows peptides and peptide-based drugs that are new or on their way: approved since the start of 2025, filed with a regulator, in a phase of human testing, announced by the developing company before any registered trial, or designed and published but not yet given to people. A row reported only in the news, not confirmed by the company, is listed as a rumour with the outlet and date. It holds 48 molecules, last checked November 4, 2026. For each one it gives the company developing it, what it targets, its phase and the source for that phase, its registered trials, its latest result, its next milestone with a date, and two explanations: one in plain words and one for readers who want the science.

A phase is not a promise. Phase 3 drugs still fail, filed drugs can be turned down, and an approval covers one product for named conditions. A molecule being in trials does not make it available: products sold online under these names outside a pharmacy are not the medicines being tested, and the companies developing them say so. Nothing here is medical advice, and the page gives no doses.

Below the tracker sits the long list: every peptide with an international nonproprietary name that has reached phase 2 or beyond in ChEMBL, with its live ClinicalTrials.gov status. For the story behind both, read the peptide drug pipeline in 2026.

At a glance

Counts of the rows below, by phase and by area of medicine. A row can sit in more than one area.

AreaRows
Obesity and diabetes23
Cardiometabolic and liver5
Rare disease11
Endocrine6
Dermatology4
Gut and liver6
Oncology and radioligands7
Antimicrobials2

Recently changed

Approvals, filings, results, trial starts and company announcements in the 90 days to November 4, 2026, newest first, each with the source that reported it.

Coming up

The next dated milestone for each molecule, soonest first (the first 15). A trial's primary completion date is the sponsor's estimate of when the last participant is measured for the main result; results usually follow months later, and sponsors move these dates.

ExpectedMoleculeMilestone
2026CagriSemaFDA decision on the weight-management application1
fourth quarter of 2026ASC37FDA investigational new drug submission for the ASC37o tablet, as the company expects1
fourth quarter of 2026Oral long-acting PTH analog (LA-PTH)FDA investigational new drug application, as the companies expect1
November 2026BulevirtidePrimary completion of a phase 2 comparing Vir's tobevibart plus elebsiran with bulevirtide3
November 13, 2026OlatorepatidePrimary completion of Regeneron's US phase 2 in overweight or obesity5
December 2026Actinium Ac 225 dotatatePrimary completion of ACTION-12
December 2026AvexitidePlanned New Drug Application submission1
December 2026RibupatidePrimary completion of the phase 3 trial in sleep apnoea with obesity3
first half of 2027PN-477Start of a phase 1 study of oral PN-477, as the company expects2
first quarter of 2027PN-881Start of a phase 2 psoriasis programme, on the strength of the phase 1 drug-level data, as the company expects3
first quarter of 2027RetatrutidePlanned US submission for obesity, sleep apnoea and knee osteoarthritis pain2
January 25, 2027Insulin icodecPrimary completion of ONWARDS 11, a further phase 3 trial3
February 10, 2027IcotrokinraPrimary completion of the ICONIC-PsA 2 phase 3 trial in psoriatic arthritis3
March 13, 2027Setmelanotide (acquired hypothalamic obesity)Primary completion of the phase 3 sub-study in congenital hypothalamic obesity3
April 27, 2027Maridebart cafraglutidePrimary completion of MARITIME-3-J in Japan, the earliest registered phase 3 completion2

Every molecule, by phase

Filter by phase or area, or search by name, company or condition. Without scripts every row shows.

48 of 48 shown

Approved in 2025-26 (12)

Approved by FDA, or by another named regulator, since January 2025, or an older drug approved for a new use in that time. The row says which.

Bulevirtide also Hepcludex, Myrcludex B

Approved in 2025-26 Gilead Sciences

What it is
Lipopeptide entry inhibitor. Target: NTCP (sodium taurocholate co-transporting polypeptide). Occupies the bile-acid transporter that hepatitis B and D viruses use to enter liver cells.
For
Chronic hepatitis D (approved in the US May 2026)
Phase
US approval May 22, 2026 (already authorised in the EU)1
Key trials
NCT03852719 NCT07142811
Last readout
April 9, 2026. MYR301 final results: virologic response in 73% to 92% of groups at end of 144 weeks; responses fell after stopping, though some patients stayed undetectable2
Next milestone
Expected November 2026. Primary completion of a phase 2 comparing Vir's tobevibart plus elebsiran with bulevirtide3

In plain words. Hepatitis D is a liver virus that needs a doorway on liver cells to get in. Bulevirtide is a daily injection that blocks that doorway, so the virus cannot infect new cells.

The science. Bulevirtide is a lipopeptide that binds the sodium taurocholate co-transporting polypeptide (NTCP), the hepatocyte bile-acid transporter that hepatitis B and D viruses use as their entry receptor, and so blocks viral entry. In the phase 3 MYR301 trial virologic and biochemical responses were maintained over 144 weeks of monotherapy. Responses fell after treatment stopped, although some patients who were undetectable at the end of treatment stayed undetectable.12

Read the encyclopedia entry

Sources (4) · last checked October 28, 2026
  1. Hepcludex (bulevirtide) US prescribing information, DailyMed set 12391cc2, version 1, effective May 22, 2026. Dated May 22, 2026. Read October 28, 2026.
  2. Wedemeyer H, et al. 144 Weeks of bulevirtide monotherapy for chronic hepatitis D: final and post-treatment results from a phase III randomized trial. J Hepatol 2026. PMID 41966308. Read October 28, 2026.
  3. ClinicalTrials.gov NCT07142811 (A Study to Evaluate Tobevibart+Elebsiran Versus Bulevirtide in Chronic HDV Infection). Read October 28, 2026.
  4. ClinicalTrials.gov NCT03852719 (Study to Assess Efficacy and Safety of Bulevirtide in Participants With Chronic Hepatitis Delta (CHD)). Read October 28, 2026.

Ecnoglutide also XW003

Approved in 2025-26 Sciwind Biosciences

What it is
cAMP-biased GLP-1 receptor agonist. Target: GLP-1 receptor. Activates the GLP-1 receptor while favouring the cAMP signal over receptor internalisation.
For
Type 2 diabetes and weight management (approved in China); Obstructive sleep apnoea; Knee osteoarthritis
Phase
Approved in China for type 2 diabetes (January 2026) and weight management (March 6, 2026); not approved in the US1
Key trials
NCT05813795 NCT07387094
Last readout
March 6, 2026. China approval for weight management on SLIMMER, a 48-week phase 3 in Chinese adults1
Next milestone
Expected December 16, 2027. Primary completion of the phase 3 trial in obstructive sleep apnoea without positive airway pressure3

In plain words. Ecnoglutide is a weekly injection that acts like the gut hormone GLP-1, which makes people feel full and helps control blood sugar. It was designed to send its signal in a slightly different way. China approved it in 2026.

The science. Ecnoglutide is a GLP-1 analogue biased toward cAMP signalling. In China it is approved for glycaemic control in type 2 diabetes, after trials such as EECOH-1, and for chronic weight management, on the SLIMMER phase 3 trial. Phase 3 trials continue in obstructive sleep apnoea and other conditions.143

Read the encyclopedia entry

Sources (4) · last checked October 28, 2026
  1. Sciwind Biosciences: ecnoglutide injection approved by China's NMPA for chronic weight management (March 6, 2026) (the company's own statement). Dated March 6, 2026. Read October 28, 2026.
  2. ClinicalTrials.gov NCT05813795 (A Phase 3 Study to Evaluate the Efficacy of XW003 in Adults With Overweight or Obesity). Read October 28, 2026.
  3. ClinicalTrials.gov NCT07387094 (A Study of XW003 in Obese Participants With Obstructive Sleep Apnea But Not Receive Positive Airway Pressure Therapy). Read October 28, 2026.
  4. Zhu D, et al. Efficacy and safety of cAMP signalling-biased GLP-1 analogue ecnoglutide monotherapy versus placebo in patients with type 2 diabetes (EECOH-1). Nat Commun 2026. PMID 41501026. Read October 28, 2026.

Elamipretide also Forzinity, SS-31, MTP-131

Approved in 2025-26 Stealth BioTherapeutics

What it is
Mitochondria-targeted tetrapeptide. Target: Cardiolipin in the inner mitochondrial membrane. Binds cardiolipin and stabilises the membrane where cells make energy.
For
Barth syndrome (approved, accelerated); Dry age-related macular degeneration (phase 3)
Phase
FDA accelerated approval September 19, 2025 for Barth syndrome; phase 3 in dry AMD13
Key trials
NCT03098797 (TAZPOWER) NCT06373731 (ReNEW) NCT07531251 (4TAZPower)
Last readout
September 19, 2025. Accelerated approval for muscle strength in Barth syndrome; continued approval depends on a confirmatory trial2
Next milestone
Expected August 2027. Primary completion of ReNEW, the phase 3 trial in dry age-related macular degeneration3

In plain words. Mitochondria are the power plants inside our cells. Elamipretide is a tiny peptide, four building blocks long, that sticks to a fat in the power plant's wall and helps it work. It is approved for Barth syndrome, a rare inherited disease of muscle and heart.

The science. Elamipretide is a cell-permeable tetrapeptide that concentrates in the inner mitochondrial membrane and binds cardiolipin, the phospholipid that is abnormal in Barth syndrome. FDA granted accelerated approval for improving muscle strength in Barth syndrome, with continued approval contingent on confirmatory trials. The ReNEW phase 3 trial tests subcutaneous elamipretide in dry age-related macular degeneration.213

Read the encyclopedia entry

Sources (5) · last checked October 28, 2026
  1. Forzinity (elamipretide) prescribing information, DailyMed set 146bf34c, version 10, effective December 10, 2025. Read October 28, 2026.
  2. Shirley M. Elamipretide: First Approval. Drugs 2025 (online December 3, 2025). PMID 41335372. Read October 28, 2026.
  3. ClinicalTrials.gov NCT06373731 (ReNEW). Read October 28, 2026.
  4. ClinicalTrials.gov NCT03098797 (TAZPOWER). Read October 28, 2026.
  5. ClinicalTrials.gov NCT07531251 (4TAZPower). Read October 28, 2026.

Enlicitide decanoate also Lipfendra, MK-0616

Approved in 2025-26 Merck (MSD)

What it is
Oral macrocyclic peptide. Target: PCSK9. Binds PCSK9 so more LDL receptors stay on liver cells.
For
High LDL cholesterol, including heterozygous familial hypercholesterolaemia (approved); Cardiovascular outcomes (in trial)
Phase
FDA approval July 15, 2026; cardiovascular outcomes trial running1
Key trials
NCT05952856 NCT05952869 NCT06450366 NCT06008756
Last readout
January 13, 2026. Phase 3 in heterozygous familial hypercholesterolaemia: LDL cholesterol fell 58.2% at week 24 against a 2.6% rise on placebo2
Next milestone
Expected November 29, 2029. Primary completion of CORALreef Outcomes, the 14,550-person cardiovascular outcomes trial4

In plain words. Enlicitide is a cholesterol pill made from a ring-shaped peptide. It blocks a protein called PCSK9, which lets the liver pull more 'bad' LDL cholesterol out of the blood.

The science. Enlicitide decanoate is an oral macrocyclic peptide inhibitor of proprotein convertase subtilisin/kexin type 9, the protein that sends LDL receptors for degradation. In phase 3 trials on top of statins it lowered LDL-C, apolipoprotein B, non-HDL cholesterol and lipoprotein(a) against placebo, and in CORALreef AddOn it lowered LDL-C more than ezetimibe, bempedoic acid or both. Whether it reduces heart attacks and strokes is the question the CORALreef Outcomes trial is built to answer.234

Read the encyclopedia entry

Sources (7) · last checked October 28, 2026
  1. FDA, Novel Drug Approvals for 2026 (Lipfendra, July 15, 2026). Dated July 15, 2026. Read October 28, 2026.
  2. Ballantyne CM, et al. Efficacy and Safety of Oral PCSK9 Inhibitor Enlicitide in Adults With Heterozygous Familial Hypercholesterolemia. JAMA 2026. PMID 41206969. Read October 28, 2026.
  3. Catapano AL, et al. Oral PCSK9 Inhibitor Enlicitide Versus Oral Nonstatin Therapies: A Phase 3 Randomized Clinical Trial. J Am Coll Cardiol 2026. PMID 42017875. Read October 28, 2026.
  4. ClinicalTrials.gov NCT06008756 (Enlicitide Decanoate (MK-0616 Oral PCSK9 Inhibitor) Cardiovascular Outcomes Study (MK-0616-015) CORALreef Outcomes). Read October 28, 2026.
  5. ClinicalTrials.gov NCT05952856 (A Study of Enlicitide Decanoate (MK-0616 Oral PCSK9 Inhibitor) in Adults With Hypercholesterolemia (MK-0616-013) CORALreef Lipids). Read October 28, 2026.
  6. ClinicalTrials.gov NCT05952869 (A Study of Enlicitide Decanoate (MK-0616 Oral PCSK9 Inhibitor) in Adults With Heterozygous Familial Hypercholesterolemia (MK-0616-017/CORALreef HeFH)). Read October 28, 2026.
  7. ClinicalTrials.gov NCT06450366 (A Study to Evaluate the Efficacy and Safety of Enlicitide (MK-0616, Oral PCSK9 Inhibitor) Compared With Ezetimibe or Bempedoic Acid or Ezetimibe and Bempedoic Acid in Adults With Hypercholesterolemia (MK-0616-018/CORALreef AddOn)). Read October 28, 2026.

Icotrokinra also Icotyde, JNJ-77242113, JNJ-2113

Approved in 2025-26 Johnson & Johnson (Janssen); discovered with Protagonist Therapeutics

What it is
Oral cyclic peptide. Target: Interleukin-23 receptor. Binds the IL-23 receptor and blocks IL-23 signalling.
For
Plaque psoriasis (approved); Psoriatic arthritis; Ulcerative colitis; Crohn's disease
Phase
FDA approval March 17, 2026 for moderate-to-severe plaque psoriasis; phase 3 in psoriatic arthritis and ulcerative colitis, phase 2b/3 in Crohn's disease14
Key trials
NCT06095115 (ICONIC-LEAD) NCT06807424 (ICONIC-PsA 2) NCT07196748 (ICONIC-UC) NCT07196722 (ICONIC-CD)
Last readout
November 6, 2025. ICONIC-LEAD: 65% clear or almost clear skin at week 16 against 8% on placebo (684 adults and adolescents)2
Next milestone
Expected February 10, 2027. Primary completion of the ICONIC-PsA 2 phase 3 trial in psoriatic arthritis3

In plain words. Icotrokinra is a small ring-shaped peptide taken as a daily pill. It blocks the receptor for a signal called IL-23 that keeps psoriasis flaring, so the skin can clear.

The science. Icotrokinra is a targeted oral peptide that selectively binds the interleukin-23 receptor, interrupting IL-23 signalling. In the phase 3 ICONIC-LEAD trial it met both co-primary endpoints (IGA 0/1 and PASI 90 at week 16) against placebo, and the share of participants with any adverse event was the same in both groups. Phase 3 trials in psoriatic arthritis and ulcerative colitis and a phase 2b/3 in Crohn's disease test it beyond the skin.2346

Read the encyclopedia entry

Sources (6) · last checked October 28, 2026
  1. FDA, Novel Drug Approvals for 2026 (Icotyde, March 17, 2026). Dated March 17, 2026. Read October 28, 2026.
  2. Bissonnette R, et al. Oral Icotrokinra for Plaque Psoriasis in Adults and Adolescents. N Engl J Med 2025;393:1784-1795 (ICONIC-LEAD). PMID 41191940. Read October 28, 2026.
  3. ClinicalTrials.gov NCT06807424 (ICONIC-PsA 2). Read October 28, 2026.
  4. ClinicalTrials.gov NCT07196748 (ICONIC-UC). Read October 28, 2026.
  5. ClinicalTrials.gov NCT06095115 (ICONIC-LEAD). Read October 28, 2026.
  6. ClinicalTrials.gov NCT07196722 (ICONIC-CD). Read October 28, 2026.

Insulin efsitora alfa also Onswik, LY3209590, basal insulin Fc

Approved in 2025-26 Eli Lilly

What it is
Once-weekly insulin-Fc fusion protein. Target: Insulin receptor. An insulin variant fused to an antibody Fc fragment, which slows its clearance to about a week.
For
Type 2 diabetes (approved); not approved for type 1
Phase
FDA approval September 23, 2026; the second weekly insulin in the US1
Key trials
NCT05362058 (QWINT-2) NCT05462756 (QWINT-4)
Last readout
September 23, 2026. FDA approval for adults with type 2 diabetes on the QWINT phase 3 programme1
Next milestone
No date announced. No further registered trial with a future completion date was found in the registry search4

In plain words. Insulin efsitora is another once-a-week insulin injection. It is approved for adults with type 2 diabetes.

The science. Insulin efsitora alfa, studied as basal insulin Fc, is a once-weekly basal insulin. A meta-analysis of five randomised trials against daily degludec found similar overall glucose control and time in range, but more time in mild hypoglycaemia and higher rates of clinically significant and severe hypoglycaemia. FDA approved it in September 2026 for adults with type 2 diabetes; it is not approved for type 1.152

Read the encyclopedia entry

Sources (5) · last checked October 28, 2026
  1. FDA, Novel Drug Approvals for 2026 (Onswik, September 23, 2026). Dated September 23, 2026. Read October 28, 2026.
  2. ClinicalTrials.gov NCT05362058 (QWINT-2). Read October 28, 2026.
  3. ClinicalTrials.gov NCT05462756 (QWINT-4). Read October 28, 2026.
  4. ClinicalTrials.gov search for insulin efsitora (read October 28, 2026): five phase 3 studies, all completed. Read October 28, 2026.
  5. Abunada S, et al. Continuous Glucose Monitoring and Hypoglycaemia Metrics With Once-Weekly Basal Insulin Fc Versus Insulin Degludec: A Systematic Review and Meta-Analysis. Endocrinol Diabetes Metab 2025. PMID 40509887. Read October 28, 2026.

Insulin icodec also Awiqli

Approved in 2025-26 Novo Nordisk

What it is
Once-weekly basal insulin analogue. Target: Insulin receptor. Binds albumin in the blood and releases insulin activity slowly over a week.
For
Type 2 diabetes (approved); not approved for type 1
Phase
FDA approval March 26, 2026 for adults with type 2 diabetes1
Key trials
NCT04460885 (ONWARDS 1) NCT07076199 (ONWARDS 11)
Last readout
March 26, 2026. FDA approval for adults with type 2 diabetes; type 1 diabetes not included1
Next milestone
Expected January 25, 2027. Primary completion of ONWARDS 11, a further phase 3 trial3

In plain words. Insulin icodec is a long-acting insulin injected once a week instead of once a day. It is approved for adults with type 2 diabetes only.

The science. Insulin icodec is a basal insulin analogue designed for once-weekly injection, tested against daily basal insulins in the ONWARDS phase 3 programme. FDA approved it in March 2026 for adults with type 2 diabetes; it is not approved for type 1 diabetes. Further phase 3 trials, such as ONWARDS 11, are still running.1423

Read the encyclopedia entry

Sources (4) · last checked October 28, 2026
  1. FDA, Novel Drug Approvals for 2026 (Awiqli, March 26, 2026). Dated March 26, 2026. Read October 28, 2026.
  2. ClinicalTrials.gov NCT04460885 (ONWARDS 1). Read October 28, 2026.
  3. ClinicalTrials.gov NCT07076199 (ONWARDS 11). Read October 28, 2026.
  4. Once-weekly insulin icodec (Awiqli) for type 2 diabetes. Med Lett Drugs Ther 2026. PMID 42752391. Read October 28, 2026.

Lutetium Lu 177 vipivotide tetraxetan also Pluvicto, 177Lu-PSMA-617

Approved in 2025-26 Novartis

What it is
Peptidomimetic radioligand. Target: Prostate-specific membrane antigen (PSMA). Carries a beta-emitting radioactive atom to PSMA on prostate cancer cells.
For
PSMA-positive metastatic prostate cancer, now including hormone-sensitive disease with ADT plus an androgen-pathway inhibitor
Phase
New indication: the label effective August 12, 2026 adds androgen-pathway-naive or -sensitive disease; first approved 20221
Key trials
NCT04720157 (PSMAddition) NCT04689828 (PSMAfore) NCT05803941
Last readout
August 6, 2026. PSMAddition: adding it to ADT plus an androgen-pathway inhibitor cut the risk of radiographic progression or death by 28% (HR 0.72)2
Next milestone
Expected July 20, 2033. Primary completion of the long-term safety study3

In plain words. This drug is a homing missile for prostate cancer. A molecule that sticks to a protein called PSMA on cancer cells carries a speck of radioactive lutetium, which damages the cancer from close range. In 2026 its use was widened to an earlier stage of the disease.

The science. Lutetium Lu 177 vipivotide tetraxetan is a PSMA-targeted radioligand: a PSMA-binding molecule carrying the beta emitter lutetium-177. In PSMAddition, a phase 3 trial in PSMA-positive metastatic hormone-sensitive prostate cancer, adding it to androgen deprivation plus an androgen-pathway inhibitor improved radiographic progression-free survival (HR 0.72). Grade 3 or worse adverse events were more frequent with the combination, without unexpected safety findings. The August 2026 label covers this use.21

Read the encyclopedia entry

Sources (5) · last checked October 28, 2026
  1. Pluvicto US prescribing information, DailyMed set 14908037, version 5, effective August 12, 2026. Dated August 12, 2026. Read October 28, 2026.
  2. Tagawa ST, et al. [177Lu]Lu-PSMA-617 in PSMA-positive metastatic androgen pathway modulator-naive/sensitive prostate cancer (PSMAddition): a phase 3 trial. Lancet 2026. PMID 42561994. Read October 28, 2026.
  3. ClinicalTrials.gov NCT05803941 (Long-Term Safety of Lutetium (177Lu) Vipivotide Tetraxetan in Participants With Prostate Cancer). Read October 28, 2026.
  4. ClinicalTrials.gov NCT04720157 (PSMAddition). Read October 28, 2026.
  5. ClinicalTrials.gov NCT04689828 (PSMAfore). Read October 28, 2026.

Mazdutide also IBI362

Approved in 2025-26 Innovent Biologics

What it is
GLP-1 and glucagon receptor dual agonist. Target: GLP-1 and glucagon receptors. Combines GLP-1 appetite and insulin effects with glucagon's effect on energy use and liver fat.
For
Weight management (approved in China); Type 2 diabetes
Phase
Approved in China, announced June 27, 2025; not approved in the US1
Key trials
NCT05607680 NCT07255209
Last readout
August 4, 2026. GLORY-2 (JAMA): clinically meaningful weight reduction against placebo in Chinese adults with moderate to severe obesity; vomiting, nausea and diarrhoea were common2
Next milestone
Expected October 31, 2027. Primary completion of the phase 3 trial in Chinese adolescents4

In plain words. Mazdutide is a weekly weight-loss injection that copies two hormones at once. One part, GLP-1, makes you feel full; the other, glucagon, helps the body use energy. China approved it in 2025; the US has not.

The science. Mazdutide is a dual agonist of the glucagon and GLP-1 receptors. China's approval for chronic weight management rested mainly on the GLORY-1 phase 3 trial; GLORY-2 tested a higher dose in adults with moderate to severe obesity and reported clinically meaningful weight reduction, with vomiting, nausea and diarrhoea common. A phase 3 trial in Chinese adolescents is running.124

Read the encyclopedia entry

Sources (4) · last checked October 28, 2026
  1. Innovent Biologics: mazdutide approved by China's NMPA for chronic weight management (June 27, 2025) (the company's own statement). Dated June 27, 2025. Read October 28, 2026.
  2. Gao L, et al. Treatment With 9-mg Mazdutide for Weight Reduction in Chinese Adults With Obesity: The GLORY-2 Randomized Clinical Trial. JAMA 2026. PMID 42251595. Read October 28, 2026.
  3. ClinicalTrials.gov NCT05607680 (A Study of IBI362 in Participants With Obesity or Overweight). Read October 28, 2026.
  4. ClinicalTrials.gov NCT07255209 (A Study of IBI362 in Chinese Adolescents With Obesity or Overweight). Read October 28, 2026.

Rusfertide also Mimrylo, PTG-300, TAK-121

Approved in 2025-26 Takeda (developed by Protagonist Therapeutics)

What it is
Hepcidin mimetic peptide. Target: Ferroportin. Mimics hepcidin, lowering the iron available for red-cell production.
For
Erythrocytosis in polycythaemia vera (approved)
Phase
FDA approval August 28, 2026; Japanese and Chinese studies registered1
Key trials
NCT05210790 (VERIFY) NCT06033586 (THRIVE) NCT07648030
Last readout
October 13, 2026. VERIFY published (J Clin Oncol): 77% of 147 patients on rusfertide had a clinical response between weeks 20 and 32, against 33% of 146 on placebo6
Next milestone
Expected October 28, 2027. Primary completion of the phase 2 study in Japanese adults4

In plain words. In polycythaemia vera the bone marrow makes far too many red blood cells, and many patients need blood taken off regularly. Rusfertide copies a natural hormone, hepcidin, that locks iron away, so the marrow cannot make as many red cells. In its main trial fewer people needed blood removed.

The science. Rusfertide is a hepcidin mimetic: like hepcidin, it acts on ferroportin, the cellular iron exporter, restricting the iron supply to red-cell production. In the phase 3 VERIFY trial fewer patients met criteria for phlebotomy than on placebo. Reviews note that the evidence rests on haematocrit and phlebotomy endpoints, and whether this lowers the risk of blood clots has not been shown.156

Read the encyclopedia entry

Sources (6) · last checked November 3, 2026
  1. FDA press announcement: FDA Approves First Drug of Its Kind for Polycythemia Vera, a Rare Blood Disorder (August 28, 2026). Dated August 28, 2026. Read October 28, 2026.
  2. ClinicalTrials.gov NCT05210790 (VERIFY). Read October 28, 2026.
  3. ClinicalTrials.gov NCT06033586 (THRIVE). Read October 28, 2026.
  4. ClinicalTrials.gov NCT07648030 (A Study of Rusfertide in Japanese Adults With Polycythemia Vera). Read October 28, 2026.
  5. Costa A, et al. Targeting the hepcidin-ferroportin axis in polycythemia vera: a complementary approach to clone-directed therapies. Blood Rev 2026. PMID 42660705. Read October 28, 2026.
  6. Kuykendall AT, et al. VERIFY: A Phase III Trial of Rusfertide Versus Placebo in Phlebotomy-Dependent Patients With Polycythemia Vera Receiving Standard-of-Care Therapy. J Clin Oncol 2026. PMID 42868322. Read November 3, 2026.

Setmelanotide (acquired hypothalamic obesity) also Imcivree

Approved in 2025-26 Rhythm Pharmaceuticals

What it is
Cyclic melanocortin-4 receptor agonist. Target: MC4R. Restores the brain's fullness signal downstream of a damaged hypothalamus.
For
Acquired hypothalamic obesity from age 4 (new US indication); Congenital hypothalamic obesity (phase 3)
Phase
New indication: the US label in effect from April 1, 2026 includes acquired hypothalamic obesity; the drug itself was first approved in 20201
Key trials
NCT05774756 NCT06760546
Last readout
July 9, 2026. TRANSCEND phase 3: significantly greater BMI and hunger reductions than placebo at 52 weeks in 120 people aged 4 to 662
Next milestone
Expected March 13, 2027. Primary completion of the phase 3 sub-study in congenital hypothalamic obesity3

In plain words. Some people gain a lot of weight after a brain tumour or injury damages the part of the brain that says 'I'm full'. Setmelanotide is a daily injection that switches on a fullness signal further down the line. Its US label now covers this kind of obesity.

The science. Setmelanotide is a melanocortin-4 receptor agonist. In the TRANSCEND phase 3 trial in acquired hypothalamic obesity, it reduced BMI and hunger scores more than placebo at 52 weeks in participants aged 4 to 66. Skin hyperpigmentation, nausea, vomiting and headache were the most common adverse events, and serious adverse events were more frequent than on placebo. The label also covers Bardet-Biedl syndrome and POMC, PCSK1 or LEPR deficiency.21

Read the encyclopedia entry

Sources (4) · last checked October 28, 2026
  1. Imcivree (setmelanotide) US prescribing information, DailyMed set 70c3ccf7, version 14, effective April 1, 2026. Dated April 1, 2026. Read October 28, 2026.
  2. Miller JL, et al. Setmelanotide for the Treatment of Acquired Hypothalamic Obesity. N Engl J Med 2026;395:138-150. PMID 42418774. Read October 28, 2026.
  3. ClinicalTrials.gov NCT06760546 (A Trial of Setmelanotide in Patients With Congenital Hypothalamic Obesity (Sub-study of NCT05774756)). Read October 28, 2026.
  4. ClinicalTrials.gov NCT05774756 (A Trial of Setmelanotide in Acquired Hypothalamic Obesity). Read October 28, 2026.

Filed with a regulator (2)

An application is with a regulator, or was returned with a complete response letter and is to be resubmitted.

CagriSema also cagrilintide and semaglutide

Filed with a regulator Novo Nordisk

What it is
Fixed combination: amylin analogue plus GLP-1 agonist. Target: Amylin/calcitonin receptors and GLP-1 receptor. Two satiety hormones' signals in one weekly injection.
For
Weight management (filed); Type 2 diabetes (phase 3)
Phase
New Drug Application submitted to FDA in December 2025; Novo said FDA would review it in 20261
Key trials
NCT05567796 (REDEFINE 1) NCT06534411 (REIMAGINE 5)
Last readout
June 22, 2025. REDEFINE 1 (NEJM 2025): weight fell 20.4% against 3.0% on placebo at 68 weeks2
Next milestone
Expected 2026. FDA decision on the weight-management application1

In plain words. CagriSema puts two weight-loss hormone copies in one weekly injection: semaglutide, the drug in Wegovy, and cagrilintide, a copy of the fullness hormone amylin. Novo Nordisk has asked the FDA to approve it.

The science. CagriSema combines cagrilintide, a long-acting amylin analogue, with the GLP-1 receptor agonist semaglutide. In REDEFINE 1, a 68-week phase 3a trial of 3,417 adults, mean weight change was -20.4% against -3.0% on placebo, and gastrointestinal adverse events affected 79.6% against 39.9%. Novo Nordisk filed the obesity application with FDA in December 2025; the REIMAGINE trials cover type 2 diabetes.214

Read the encyclopedia entry

Sources (4) · last checked October 28, 2026
  1. Novo Nordisk: files for FDA approval of CagriSema (December 18, 2025) (the company's own statement). Dated December 18, 2025. Read October 28, 2026.
  2. Garvey WT, et al. Coadministered Cagrilintide and Semaglutide in Adults with Overweight or Obesity. N Engl J Med 2025;393:635-647. PMID 40544433. Read October 28, 2026.
  3. ClinicalTrials.gov NCT05567796 (REDEFINE 1). Read October 28, 2026.
  4. ClinicalTrials.gov NCT06534411 (REIMAGINE 5). Read October 28, 2026.

Lutetium Lu 177 edotreotide also ITM-11, 177Lu-DOTATOC

Filed with a regulator ITM Isotope Technologies Munich

What it is
Somatostatin-analogue radioligand. Target: Somatostatin receptor 2. Carries lutetium-177 to neuroendocrine tumour cells that display somatostatin receptors.
For
Gastroenteropancreatic neuroendocrine tumours (filed)
Phase
NDA accepted with an August 28, 2026 goal date; FDA issued a complete response letter on August 7, 2026 citing manufacturing (CMC) and a third-party facility, not the clinical data; ITM plans to resubmit12
Key trials
NCT03049189 (COMPETE) NCT04919226 (COMPOSE)
Last readout
August 7, 2026. Complete response letter on manufacturing grounds; no clinical or safety concerns raised, the company says1
Next milestone
Expected June 2027. Primary completion of COMPOSE, the second phase 3 trial (grade 2-3 tumours)4

In plain words. Neuroendocrine tumours often carry a 'docking site' for the hormone somatostatin. This drug is a somatostatin look-alike carrying a radioactive atom, so it delivers radiation straight to the tumour. The FDA asked for manufacturing fixes before it can approve it.

The science. Lutetium Lu 177 edotreotide (DOTATOC) is a somatostatin-analogue radioligand. In the COMPETE phase 3 trial in grade 1-2 gastroenteropancreatic neuroendocrine tumours, median progression-free survival was 23.9 months against 14.1 months on everolimus (HR 0.67). FDA's August 2026 complete response letter concerned chemistry, manufacturing and controls and a third-party facility, according to the company. COMPOSE tests it against standard therapy in higher-grade tumours.314

Read the encyclopedia entry

Sources (5) · last checked October 28, 2026
  1. ITM: receives complete response letter for 177Lu-edotreotide (ITM-11) (August 10, 2026) (the company's own statement). Dated August 10, 2026. Read October 28, 2026.
  2. ITM: FDA acceptance of NDA and PDUFA date for n.c.a. 177Lu-edotreotide (November 13, 2025) (the company's own statement). Dated November 13, 2025. Read October 28, 2026.
  3. Walter T, et al. [177Lu]Lu-edotreotide versus everolimus for gastroenteropancreatic neuroendocrine tumours (COMPETE): a phase 3 trial. Lancet 2026. PMID 42392118. Read October 28, 2026.
  4. ClinicalTrials.gov NCT04919226 (COMPOSE). Read October 28, 2026.
  5. ClinicalTrials.gov NCT03049189 (COMPETE). Read October 28, 2026.

Phase 3 (24)

Large trials that decide whether a drug is approved. The phase is the highest phase among the row's own registered trials.

Actinium Ac 225 dotatate also RYZ101, 225Ac-DOTATATE

Phase 3 RayzeBio

What it is
Alpha-emitting somatostatin-analogue radioligand. Target: Somatostatin receptor 2. Delivers an alpha-emitting atom, which causes dense, short-range DNA damage, to SSTR2-positive tumours.
For
Neuroendocrine tumours after lutetium-177 therapy; Small-cell lung cancer, breast cancer, meningioma (early trials)
Phase
ACTION-1 phase 1b/32
Key trials
NCT05477576 (ACTION-1)
Last readout
August 3, 2026. ACTION-1 phase 1b dosimetry (J Nucl Med): favourable tumour-to-normal-tissue absorbed dose ratios1
Next milestone
Expected December 2026. Primary completion of ACTION-12

In plain words. This is a radioactive cancer drug for neuroendocrine tumours that keep growing after an older radioactive treatment. It uses actinium, which gives off very strong radiation over a tiny distance.

The science. RYZ101 is DOTATATE, a somatostatin analogue, carrying actinium-225, an alpha emitter whose particles deliver high energy over a short path and cause largely irreparable double-strand DNA breaks. ACTION-1 randomises patients with SSTR-positive GEP-NETs that progressed after lutetium-177 somatostatin-analogue therapy to RYZ101 or standard care. Dosimetry from its phase 1b part found a favourable tumour-to-normal-tissue absorbed dose ratio.12

Sources (2) · last checked October 28, 2026
  1. Sgouros G, et al. Dosimetry Results from the Phase 1b/3 ACTION-1 Trial of [225Ac]Ac-DOTATATE (RYZ101). J Nucl Med 2026;67:1239-1246. PMID 42242867. Read October 28, 2026.
  2. ClinicalTrials.gov NCT05477576 (ACTION-1). Read October 28, 2026.

Actinium Ac 225 zadavotide guraxetan also AZD2265, FPI-2265, 225Ac-PSMA-I&T

Phase 3 AstraZeneca

What it is
Alpha-emitting PSMA radioligand. Target: PSMA. Delivers actinium-225 to PSMA-positive prostate cancer.
For
Metastatic castration-resistant prostate cancer after lutetium-177 PSMA therapy
Phase
VECTRA-01 phase 3 started May 20261
Key trials
NCT07611110 (VECTRA-01)
Last readout
No results reported yet in the sources read.
Next milestone
Expected June 4, 2029. Primary completion of VECTRA-011

In plain words. This drug carries a strong but short-range radioactive atom, actinium, to prostate cancer cells that display PSMA. It is being tested in men whose cancer kept growing after an earlier PSMA radiation drug.

The science. AZD2265 (FPI-2265) is 225Ac-PSMA-I&T. VECTRA-01 randomises men with PSMA-positive metastatic castration-resistant prostate cancer previously treated with a beta-emitting PSMA radioconjugate, a taxane and an androgen-pathway inhibitor to AZD2265 or standard therapy, with radiographic progression-free survival and overall survival as primary endpoints.1

Read the encyclopedia entry

Sources (1) · last checked October 28, 2026
  1. ClinicalTrials.gov NCT07611110 (VECTRA-01). Read October 28, 2026.

Afamelanotide (vitiligo) also Scenesse, CUV105

Phase 3 Clinuvel

What it is
Alpha-MSH analogue (melanocortin-1 receptor agonist). Target: MC1R. Stimulates melanocytes to make pigment, alongside narrow-band UVB light.
For
Vitiligo (phase 3; new indication); Erythropoietic protoporphyria (approved 2019)
Phase
Phase 3 CUV105 with narrow-band UVB; the drug is already approved for erythropoietic protoporphyria2
Key trials
NCT06109649
Last readout
2015. Earlier randomised trial (JAMA Dermatology): afamelanotide plus NB-UVB gave faster repigmentation than NB-UVB alone1
Next milestone
Expected December 2025. CUV105 results; the registered primary completion estimate (December 2025) has passed without an update2 That date has passed without an update in the source.

In plain words. Vitiligo causes white patches where the skin's pigment cells have stopped working. Afamelanotide copies a natural tanning hormone. Combined with a special light treatment, it helped colour come back faster in an earlier trial.

The science. Afamelanotide is a melanocortin-1 receptor agonist that stimulates melanin production. In a randomised trial, afamelanotide plus narrow-band UVB gave faster and greater repigmentation than narrow-band UVB alone, most clearly in darker skin types. The phase 3 CUV105 trial compares the same combination; its registered completion estimate has passed without an update.12

Read the encyclopedia entry

Sources (2) · last checked October 28, 2026
  1. Lim HW, et al. Afamelanotide and narrowband UV-B phototherapy for the treatment of vitiligo: a randomized multicenter trial. JAMA Dermatol 2015. PMID 25230094. Read October 28, 2026.
  2. ClinicalTrials.gov NCT06109649 (A Study to Compare the Efficacy and Safety of SCENESSE and Narrow-Band Ultraviolet (NB-UVB) Light Versus NB-UVB Light Alone in Patients With Vitiligo). Read October 28, 2026.

Amycretin also NNC0487-0111

Phase 3 Novo Nordisk

What it is
Unimolecular GLP-1 and amylin receptor agonist. Target: GLP-1 and amylin receptors. One peptide that activates both GLP-1 and amylin receptors; weekly injection and an oral form.
For
Obesity; Obstructive sleep apnoea; Type 2 diabetes
Phase
AMAZE phase 3 programme registered under NNC0487-0111 from April 20262
Key trials
NCT07503210 (AMAZE 12) NCT07571005 (AMAZE 3)
Last readout
June 20, 2025. Phase 1b/2a (Lancet): weight fell 24.3% against 1.1% on placebo at 36 weeks in the highest-dose group1
Next milestone
Expected June 6, 2028. Primary completion of AMAZE 122

In plain words. Amycretin is one molecule that does the job of two fullness hormones, GLP-1 and amylin. Early trials showed large weight loss, and big trials started in 2026.

The science. Amycretin is a unimolecular agonist of the GLP-1 and amylin receptors, rather than a combination of two molecules as in CagriSema. In a subcutaneous phase 1b/2a study, weight fell substantially more than on placebo, and gastrointestinal events were frequent, at rates similar to early studies of each agonist class. Novo Nordisk registers the AMAZE phase 3 trials under its code NNC0487-0111.12

Read the encyclopedia entry

Sources (3) · last checked October 28, 2026
  1. Dahl K, et al. Amycretin, a novel, unimolecular GLP-1 and amylin receptor agonist administered subcutaneously: phase 1b/2a. Lancet 2025. PMID 40550231. Read October 28, 2026.
  2. ClinicalTrials.gov NCT07503210 (AMAZE 12). Read October 28, 2026.
  3. ClinicalTrials.gov NCT07571005 (AMAZE 3). Read October 28, 2026.

Apraglutide also FE 203799

Phase 3 VectivBio

What it is
Once-weekly GLP-2 analogue. Target: GLP-2 receptor. Weekly GLP-2 mimic for bowel adaptation.
For
Short bowel syndrome with intestinal failure
Phase
STARS-2 phase 3 recruiting since August 20262
Key trials
NCT04627025 (STARS) NCT07742735 (STARS-2)
Last readout
September 3, 2026. STARS (Clin Gastroenterol Hepatol): weekly apraglutide significantly reduced parenteral support volume; the 48-week secondary comparisons were not significant1
Next milestone
Expected October 2028. Primary completion of STARS-22

In plain words. Apraglutide is a once-a-week version of the gut hormone GLP-2 for people with short bowel syndrome. It helps the remaining gut absorb more, so they need less drip feeding.

The science. Apraglutide is a once-weekly GLP-2 analogue. In the STARS phase 3 trial it significantly reduced parenteral support requirements against placebo; at week 48 the days-off and enteral-autonomy comparisons were not statistically significant. STARS-2 is a second placebo-controlled phase 3.12

Read the encyclopedia entry

Sources (3) · last checked October 28, 2026
  1. Joly F, et al. STARS Phase 3 Trial: Once-Weekly Apraglutide Reduces Parenteral Support in Short Bowel Syndrome-Intestinal Failure. Clin Gastroenterol Hepatol 2026. PMID 42692160. Read October 28, 2026.
  2. ClinicalTrials.gov NCT07742735 (STARS-2). Read October 28, 2026.
  3. ClinicalTrials.gov NCT04627025 (STARS). Read October 28, 2026.

Avexitide also exendin (9-39)

Phase 3 Amylyx Pharmaceuticals

What it is
GLP-1 receptor antagonist peptide. Target: GLP-1 receptor. Blocks the GLP-1 receptor to stop the insulin surges that cause low blood sugar after gastric bypass.
For
Post-bariatric hypoglycaemia
Phase
Phase 3 LUCIDITY positive (August 18, 2026); Amylyx plans to submit an NDA by the end of 202621
Key trials
NCT06747468 (LUCIDITY)
Last readout
August 18, 2026. LUCIDITY: 55% fewer level 2 and 3 hypoglycaemia events than placebo through week 16 (company release)1
Next milestone
Expected December 2026. Planned New Drug Application submission1

In plain words. After some weight-loss surgeries, the body can release too much insulin after a meal and blood sugar can crash. Avexitide blocks the GLP-1 signal that drives that insulin rush. Its main trial worked, and the company plans to apply for approval by the end of 2026.

The science. Avexitide is a GLP-1 receptor antagonist peptide (exendin 9-39). In post-bariatric hypoglycaemia, blocking the receptor blunts the exaggerated insulin response after meals. The phase 3 LUCIDITY trial met its primary endpoint on the rate of level 2 and level 3 hypoglycaemic events through week 16, and a phase 2b study was published in 2026.123

Read the encyclopedia entry

Sources (3) · last checked October 28, 2026
  1. Amylyx Pharmaceuticals, Form 8-K exhibit 99.1: LUCIDITY phase 3 topline results (August 18, 2026) (the company's own statement). Dated August 18, 2026. Read October 28, 2026.
  2. ClinicalTrials.gov NCT06747468 (LUCIDITY). Read October 28, 2026.
  3. Craig C, et al. Efficacy and safety of avexitide for hypoglycemia following bariatric and other upper gastrointestinal surgeries: a phase 2b study. PMID 42744082. Read October 28, 2026.

Berobenatide also PF-08653944, MET-097i, MET097

Phase 3 Pfizer; first developed by Metsera as MET-097i

What it is
Ultra-long-acting GLP-1 receptor agonist. Target: GLP-1 receptor. A long-lasting GLP-1 receptor agonist peptide that Pfizer describes as fully biased, given by injection weekly or, after a weekly start, monthly.
For
Obesity and overweight; Obesity with type 2 diabetes; Obstructive sleep apnoea with obesity; Knee osteoarthritis with obesity
Phase
Pfizer's pipeline update of November 3, 2026 lists it in phase 3 for chronic weight management; eleven phase 3 trials are registered, the newest (VESPER-OA 2, knee osteoarthritis) posted November 4, 20261414
Key trials
NCT07311850 (VESPER-4) NCT07400653 NCT07595549 NCT07792954 NCT07794761 NCT07794774 NCT07823608 NCT07845500 NCT07874633 NCT07881757 (VESPER-OSA 2) NCT07915609
Last readout
February 3, 2026. VESPER-3 phase 2b: up to 12.3% placebo-adjusted weight loss at 28 weeks after the switch from weekly to monthly dosing (10.5% counting everyone randomised); weight was still falling (company release)2
Next milestone
Expected September 21, 2027. Primary completion of VESPER-4, the 3,578-person weekly phase 3 in overweight or obesity4

In plain words. Berobenatide is a weight-loss injection that copies the gut hormone GLP-1, like semaglutide, but lasts long enough that Pfizer is testing it once a month. It is in large phase 3 trials and is not approved anywhere.

The science. Berobenatide (PF-08653944, formerly Metsera's MET-097i) is a GLP-1 receptor agonist peptide built for an albumin-like half-life, which its developer calls fully biased. In the phase 2b VESPER-3 trial, Pfizer reports weight loss that kept going after people moved from weekly to monthly injections. The phase 3 VESPER programme tests weekly and monthly doses in obesity, type 2 diabetes, sleep apnoea and knee osteoarthritis, in Japan and China, and as a switch from weekly semaglutide or tirzepatide.23111

Sources (14) · last checked November 4, 2026
  1. Pfizer pipeline update, November 3, 2026 (berobenatide, phase 3, chronic weight management) (the company's own statement). Dated November 3, 2026. Read November 4, 2026.
  2. Pfizer: ultra-long-acting injectable GLP-1 RA, VESPER-3 phase 2b results (information as of February 3, 2026) (the company's own statement). Dated February 3, 2026. Read November 4, 2026.
  3. Metsera: VESPER-1 phase 2b results for MET-097i, which it calls its foundational peptide (September 29, 2025) (the company's own statement). Dated September 29, 2025. Read November 4, 2026.
  4. ClinicalTrials.gov NCT07311850 (VESPER-4). Read November 4, 2026.
  5. ClinicalTrials.gov NCT07400653 (VESPER-5, with type 2 diabetes). Read November 4, 2026.
  6. ClinicalTrials.gov NCT07595549 (VESPER-6, monthly). Read November 4, 2026.
  7. ClinicalTrials.gov NCT07792954 (weekly, Chinese adults). Read November 4, 2026.
  8. ClinicalTrials.gov NCT07794761 (VESPER-JW, weekly, Japan). Read November 4, 2026.
  9. ClinicalTrials.gov NCT07794774 (VESPER-JM, monthly, Japan). Read November 4, 2026.
  10. ClinicalTrials.gov NCT07823608 (VESPER-OSA 1). Read November 4, 2026.
  11. ClinicalTrials.gov NCT07845500 (VESPER-SWITCH). Read November 4, 2026.
  12. ClinicalTrials.gov NCT07874633 (monthly, Chinese adults). Read November 4, 2026.
  13. ClinicalTrials.gov NCT07881757 (VESPER-OSA 2). Read November 4, 2026.
  14. ClinicalTrials.gov NCT07915609 (VESPER-OA 2, knee osteoarthritis). Read November 4, 2026.

Cagrilintide also NN9838

Phase 3 Novo Nordisk

What it is
Long-acting amylin analogue. Target: Amylin and calcitonin receptors. Weekly amylin mimic that signals fullness.
For
Weight management on its own (phase 3)
Phase
Phase 3 trials of cagrilintide alone, separate from CagriSema2
Key trials
NCT07220642 (RENEW 1)
Last readout
November 16, 2021. Phase 2 (Lancet): significant, dose-dependent weight reduction against placebo over 26 weeks1
Next milestone
Expected May 11, 2027. Primary completion of RENEW 1, a phase 3 trial of cagrilintide alone2

In plain words. Cagrilintide is a weekly copy of amylin, a fullness hormone. It is best known as half of CagriSema, but Novo Nordisk is also testing it on its own.

The science. Cagrilintide is a long-acting amylin analogue. As monotherapy it produced significant weight reduction against placebo in a phase 2 trial, with gastrointestinal events and injection-site reactions the most frequent adverse events. A stand-alone phase 3 trial, RENEW 1, began in November 2025.12

Read the encyclopedia entry

Sources (2) · last checked October 28, 2026
  1. Lau DCW, et al. Once-weekly cagrilintide for weight management in people with overweight and obesity: a phase 2 trial. Lancet 2021. PMID 34798060. Read October 28, 2026.
  2. ClinicalTrials.gov NCT07220642 (RENEW 1). Read October 28, 2026.

Eloralintide also LY3841136, EloraTZP (with tirzepatide)

Phase 3 Eli Lilly

What it is
Selective amylin receptor agonist. Target: Amylin receptors. Mimics amylin, a hormone released with insulin that slows the stomach and signals fullness.
For
Obesity; Knee osteoarthritis pain; Obstructive sleep apnoea; With tirzepatide as EloraTZP
Phase
Five ENLIGHTEN phase 3 trials recruiting; two EloraTZP phase 3 trials registered2
Key trials
NCT06230523 NCT06603571 NCT07321886 (ENLIGHTEN-1) NCT07881432 (AMPLIFY-1)
Last readout
November 6, 2025. Phase 2 (Lancet): dose-dependent weight loss over 48 weeks against -0.4% on placebo; nausea and fatigue the common adverse events1
Next milestone
Expected March 2028. Primary completion of ENLIGHTEN-1 in obesity without diabetes2

In plain words. Amylin is a hormone your pancreas releases alongside insulin after a meal; it helps tell your brain you have eaten enough. Eloralintide is a long-lasting weekly copy of it being tested for weight loss, alone and paired with tirzepatide.

The science. Eloralintide is a selective amylin receptor agonist. In a 48-week phase 2 trial it produced dose-dependent weight reduction against placebo, with nausea and fatigue the most common adverse events. Lilly is testing it alone in the ENLIGHTEN phase 3 trials and with tirzepatide (EloraTZP) in AMPLIFY.123

Read the encyclopedia entry

Sources (5) · last checked October 28, 2026
  1. Billings LK, et al. Eloralintide, a selective amylin receptor agonist for the treatment of obesity: a 48-week phase 2 trial. Lancet 2025. PMID 41207310. Read October 28, 2026.
  2. ClinicalTrials.gov NCT07321886 (ENLIGHTEN-1). Read October 28, 2026.
  3. ClinicalTrials.gov NCT07881432 (AMPLIFY-1). Read October 28, 2026.
  4. ClinicalTrials.gov NCT06230523 (A Study of LY3841136 Compared With Placebo in Adult Participants With Obesity or Overweight). Read October 28, 2026.
  5. ClinicalTrials.gov NCT06603571 (A Study to Investigate Weight Management With LY3841136 and Tirzepatide (LY3298176), Alone or in Combination, in Adult Participants With Obesity or Overweight With Type 2 Diabetes). Read October 28, 2026.

Eneboparatide also AZP-3601

Phase 3 AstraZeneca (Alexion)

What it is
Parathyroid hormone receptor agonist peptide. Target: PTH1 receptor. Long-acting PTH-receptor agonist designed to hold blood calcium steady.
For
Chronic hypoparathyroidism
Phase
Phase 3 CALYPSO positive; two-year extension ongoing21
Key trials
NCT05778071 (CALYPSO)
Last readout
May 12, 2026. CALYPSO week 24: 31.1% normalised serum calcium off active vitamin D and with little calcium, against 5.9% on placebo (company release)1
Next milestone
Expected June 16, 2027. Study completion of CALYPSO, including the long-term period (registry estimate)2

In plain words. When the parathyroid glands stop working, calcium in the blood drops and people need many pills a day. Eneboparatide is a daily injection that copies parathyroid hormone to keep calcium normal. In its main trial about a third of patients could stop their supplements.

The science. Eneboparatide is a parathyroid hormone receptor agonist developed as a long-acting PTH analogue. CALYPSO's composite primary endpoint required normal albumin-adjusted serum calcium without active vitamin D and with little oral calcium at week 24; it was met, and urinary calcium normalised more often than on placebo in those hypercalciuric at baseline, according to the company. A two-year extension is ongoing.132

Read the encyclopedia entry

Sources (3) · last checked October 28, 2026
  1. AstraZeneca: eneboparatide normalised serum calcium and achieved independence from supplements in 31.1% of adults with hypoparathyroidism at week 24 in CALYPSO (May 12, 2026) (the company's own statement). Dated May 12, 2026. Read October 28, 2026.
  2. ClinicalTrials.gov NCT05778071 (CALYPSO). Read October 28, 2026.
  3. Brandi ML, et al. Hypoparathyroidism: translating science from the laboratory to the clinic. Lancet Diabetes Endocrinol 2026. PMID 42705258. Read October 28, 2026.

Enicepatide also CT-388, RO7795068

Phase 3 Roche (from Carmot Therapeutics)

What it is
Signalling-biased GLP-1 and GIP receptor dual agonist. Target: GLP-1 and GIP receptors. Activates both incretin receptors while limiting receptor internalisation.
For
Obesity; Obesity with type 2 diabetes
Phase
Enith phase 3 programme started March 2026; a head-to-head with tirzepatide is registered2
Key trials
NCT07351045 (Enith1) NCT07351058 (Enith2) NCT06628362
Last readout
November 28, 2025. Phase 1b and preclinical report (Mol Metab): cAMP-biased dual agonism reduced weight and improved glycaemia in participants with obesity1
Next milestone
Expected July 24, 2028. Primary completion of Enith1 (obesity without diabetes)2

In plain words. Enicepatide is a weekly injection that, like tirzepatide, copies two gut hormones, GLP-1 and GIP. It was built to switch the receptors on without making them shut down as quickly. Its large trials began in 2026.

The science. Enicepatide (CT-388) is a unimolecular peptide agonist of the GLP-1 and GIP receptors that is cAMP-signal-biased, with minimal receptor internalisation. Preclinical and early clinical work reported weight loss and improved glycaemic control. Roche sponsors the Enith phase 3 trials.12

Read the encyclopedia entry

Sources (4) · last checked October 28, 2026
  1. Chakravarthy MV, et al. Effects of CT-388, a once-weekly signaling-biased dual GLP-1/GIP receptor agonist, in preclinical models and participants with obesity. Mol Metab 2025. PMID 41319798. Read October 28, 2026.
  2. ClinicalTrials.gov NCT07351045 (Enith1). Read October 28, 2026.
  3. ClinicalTrials.gov NCT07351058 (Enith2). Read October 28, 2026.
  4. ClinicalTrials.gov NCT06628362 (A Study of Enicepatide (CT-388) in Participants Who Are Overweight or Obese With Type 2 Diabetes Mellitus). Read October 28, 2026.

Glepaglutide also ZP1848

Phase 3 Zealand Pharma

What it is
Long-acting GLP-2 analogue. Target: GLP-2 receptor. Stimulates growth and absorption in the remaining bowel.
For
Short bowel syndrome with intestinal failure
Phase
A new confirmatory phase 3 (EASE SBS 5) began February 20262
Key trials
NCT03690206 (EASE SBS 1) NCT07197944 (EASE SBS 5) NCT07228403 (EASE SBS 6)
Last readout
December 19, 2024. EASE SBS 1 (Gastroenterology): twice-weekly dosing cut parenteral support more than placebo; once-weekly dosing did not separate from placebo1
Next milestone
Expected October 23, 2028. Primary completion of EASE SBS 52

In plain words. People who have lost much of their small intestine often need nutrition through a drip. Glepaglutide copies a gut hormone, GLP-2, that helps the remaining bowel absorb more. It is in a new large trial to confirm earlier results.

The science. Glepaglutide is a long-acting GLP-2 analogue designed for a ready-to-use liquid formulation. In EASE SBS 1 the twice-weekly regimen reduced parenteral support more than placebo; the once-weekly regimen did not differ significantly. EASE SBS 5 is a new placebo-controlled phase 3 of the twice-weekly regimen.512

Read the encyclopedia entry

Sources (5) · last checked October 28, 2026
  1. Jeppesen PB, et al. Glepaglutide, a Long-Acting GLP-2 Analogue, Reduces Parenteral Support in Patients With Short Bowel Syndrome: A Phase 3 Trial. Gastroenterology 2024. PMID 39708985. Read October 28, 2026.
  2. ClinicalTrials.gov NCT07197944 (EASE SBS 5). Read October 28, 2026.
  3. ClinicalTrials.gov NCT03690206 (EASE SBS 1). Read October 28, 2026.
  4. ClinicalTrials.gov NCT07228403 (EASE SBS 6). Read October 28, 2026.
  5. Larsen BD, et al. Creating Glepaglutide, the First Long-Acting GLP-2 Analogue to Enable a Ready-to-Use Injection. J Med Chem 2025. PMID 39851172. Read October 28, 2026.

Lenbelintide also AZD6234

Phase 3 AstraZeneca

What it is
Long-acting selective amylin receptor agonist. Target: Amylin receptors. Weekly amylin mimic, tested alone and as an add-on to GLP-1 drugs.
For
Obesity; Type 2 diabetes; Add-on to incretin therapy
Phase
SELENE phase 3 programme started August 20262
Key trials
NCT07784725 (SELENE 1) NCT07776509 (SELENE 3) NCT06851858 (ARAY)
Last readout
May 26, 2026. Phase 2 ARAY reached primary completion; no results were posted on the registry when read4
Next milestone
Expected August 11, 2028. Primary completion of SELENE 12

In plain words. Lenbelintide is AstraZeneca's weekly copy of the fullness hormone amylin. It is being tested on its own and on top of GLP-1 medicines.

The science. Lenbelintide (AZD6234) is a long-acting amylin analogue. SELENE 1 tests it alone in obesity without diabetes, and SELENE 3 tests it as an adjunct to incretin-based therapy. Its phase 2 trial reached primary completion in May 2026.1234

Read the encyclopedia entry

Sources (4) · last checked October 28, 2026
  1. Alhazmi A, et al. Amylin Analogs: The Next Major Class of Weight Loss Therapy: A Review of Experimental Data and Early-Phase Clinical Trials. Diabetes Obes Metab 2026. PMID 42452898. Read October 28, 2026.
  2. ClinicalTrials.gov NCT07784725 (SELENE 1). Read October 28, 2026.
  3. ClinicalTrials.gov NCT07776509 (SELENE 3). Read October 28, 2026.
  4. ClinicalTrials.gov NCT06851858 (ARAY). Read October 28, 2026.

Lutetium Lu 177 PSMA-I&T also 177Lu-PSMA-I&T, ECLIPSE

Phase 3 Curium

What it is
Beta-emitting PSMA radioligand. Target: PSMA. Delivers lutetium-177 to PSMA-positive prostate cancer.
For
Metastatic castration-resistant prostate cancer after an androgen-pathway inhibitor
Phase
ECLIPSE phase 3 met its primary endpoint (November 2024); no filing date in the company's release21
Key trials
NCT05204927
Last readout
November 13, 2024. ECLIPSE met its primary endpoint: longer radiographic progression-free survival than switching hormone therapy (company release)1
Next milestone
No date announced. Regulatory submission; Curium said it would develop a submission plan with FDA as data mature, without a date1

In plain words. This is another radioactive drug aimed at the PSMA marker on prostate cancer cells, from a different company than Pluvicto. Its main trial slowed the cancer more than switching to a different hormone pill.

The science. 177Lu-PSMA-I&T is a lutetium-177-labelled PSMA ligand. ECLIPSE randomised patients with PSMA-positive metastatic castration-resistant prostate cancer previously treated with an androgen-pathway inhibitor to 177Lu-PSMA-I&T or a change of hormone therapy, and the company reported that it met its radiographic progression-free survival endpoint. No peer-reviewed full report was among the sources read.12

Read the encyclopedia entry

Sources (2) · last checked October 28, 2026
  1. Curium: ECLIPSE trial met its primary endpoint (November 13, 2024) (the company's own statement). Dated November 13, 2024. Read October 28, 2026.
  2. ClinicalTrials.gov NCT05204927 (177Lu-PSMA-I&T for Metastatic Castration-Resistant Prostate Cancer). Read October 28, 2026.

Maridebart cafraglutide also MariTide, AMG 133

Phase 3 Amgen

What it is
Peptide-antibody conjugate. Target: GLP-1 receptor (agonist) and GIP receptor (antagonist). Two GLP-1 agonist peptides attached to an antibody that blocks the GIP receptor; dosed monthly.
For
Obesity; Type 2 diabetes; Obstructive sleep apnoea; Heart failure
Phase
MARITIME phase 3 programme2
Key trials
NCT05669599 NCT06987695 (MARITIME-3-J) NCT07225686 (MARITIME-OSA-1)
Last readout
June 23, 2025. Phase 2 (NEJM): weight fell 12.3% to 16.2% against 2.5% on placebo at 52 weeks in people without diabetes1
Next milestone
Expected April 27, 2027. Primary completion of MARITIME-3-J in Japan, the earliest registered phase 3 completion2

In plain words. MariTide joins two GLP-1-like peptides to an antibody. The antibody makes it last long enough for a monthly injection, and it also blocks a second hormone receptor called GIP. It is in large trials for obesity.

The science. Maridebart cafraglutide is a long-acting peptide-antibody conjugate that combines GLP-1 receptor agonism with GIP receptor antagonism. In a 52-week phase 2 trial with dosing every four weeks, it produced substantial weight reduction in people with obesity with or without type 2 diabetes. Gastrointestinal adverse events were common and less frequent with dose escalation and a lower starting dose.12

Read the encyclopedia entry

Sources (4) · last checked October 28, 2026
  1. Jastreboff AM, et al. Once-Monthly Maridebart Cafraglutide for the Treatment of Obesity - A Phase 2 Trial. N Engl J Med 2025;393:843-857. PMID 40549887. Read October 28, 2026.
  2. ClinicalTrials.gov NCT06987695 (MARITIME-3-J). Read October 28, 2026.
  3. ClinicalTrials.gov NCT05669599 (Dose-ranging Study to Evaluate the Efficacy, Safety, and Tolerability of AMG 133 in Adult Subjects With Overweight or Obesity, With or Without Type 2 Diabetes Mellitus). Read October 28, 2026.
  4. ClinicalTrials.gov NCT07225686 (MARITIME-OSA-1). Read October 28, 2026.

Olatorepatide also HS-20094

Phase 3 Hansoh Pharma (China); Regeneron (outside China)

What it is
Dual-biased GLP-1 and GIP receptor agonist. Target: GLP-1 and GIP receptors. Weekly incretin dual agonist in the tirzepatide class.
For
Obesity; Type 2 diabetes; Hidradenitis suppurativa (phase 2)
Phase
Phase 3 completed in China (LIGHTEN); Regeneron's global phase 3 RISE-1 registered34
Key trials
NCT06839664 NCT07896265 (RISE-1) NCT07431086
Last readout
October 2, 2026. LIGHTEN (604 Chinese adults): weight fell 11.8%, 17.0% and 18.7% on three doses against 2.5% on placebo at 48 weeks, counting everyone randomised (company release)1
Next milestone
Expected November 13, 2026. Primary completion of Regeneron's US phase 2 in overweight or obesity5

In plain words. Olatorepatide is a weekly weight-loss injection that copies the gut hormones GLP-1 and GIP, like tirzepatide. Its first large trial in China reported in October 2026, and Regeneron is testing it in other countries.

The science. Olatorepatide (HS-20094) is a GLP-1 and GIP receptor dual agonist that its developer describes as dual-biased. Hansoh reported the LIGHTEN phase 3 results under both treatment-regimen and efficacy estimands. Regeneron licensed rights outside mainland China, Hong Kong and Macau in June 2025 and has registered phase 2 and phase 3 trials, including one in hidradenitis suppurativa.124

Read the encyclopedia entry

Sources (5) · last checked October 28, 2026
  1. Hansoh Pharma (EQS release): 19.3% weight loss at week 48, phase 3 data of olatorepatide presented at EASD (October 2, 2026) (the company's own statement). Dated October 2, 2026. Read October 28, 2026.
  2. Regeneron: in-licensing of HS-20094 from Hansoh (June 2, 2025) (the company's own statement). Dated June 2, 2025. Read October 28, 2026.
  3. ClinicalTrials.gov NCT06839664 (A Study of HS-20094 in Chinese Adults With Overweight or Obesity). Read October 28, 2026.
  4. ClinicalTrials.gov NCT07896265 (RISE-1). Read October 28, 2026.
  5. ClinicalTrials.gov NCT07431086 (Study of Olatorepatide in Adult Participants Living With Overweight or Obesity in the US). Read October 28, 2026.

Pemvidutide also ALT-801

Phase 3 Altimmune

What it is
GLP-1 and glucagon receptor dual agonist. Target: GLP-1 and glucagon receptors. Balanced dual agonist aimed at liver fat and inflammation.
For
MASH (fatty liver disease with inflammation); Alcohol-associated liver disease (phase 2)
Phase
Phase 3 PERFORMA in MASH started July 30, 20262
Key trials
NCT05989711 (IMPACT) NCT07795164 (PERFORMA) NCT07009860
Last readout
November 11, 2025. IMPACT phase 2b (Lancet): MASH resolution in 58% and 52% against 20% on placebo at 24 weeks; the fibrosis endpoint was not met1
Next milestone
Expected September 30, 2027. Primary completion of RESTORE, the phase 2 trial in alcohol-associated liver disease3

In plain words. Pemvidutide is a weekly injection being tested for a serious kind of fatty liver disease called MASH. In its main trial it cleared the liver inflammation in about half of people, but did not yet improve scarring.

The science. Pemvidutide is a GLP-1 and glucagon receptor dual agonist. In IMPACT, a phase 2b trial in biopsy-confirmed MASH with F2-F3 fibrosis, it met the MASH-resolution endpoint at 24 weeks but not the fibrosis-improvement endpoint. The phase 3 PERFORMA trial began in July 2026, and RESTORE studies alcohol-associated liver disease.123

Read the encyclopedia entry

Sources (4) · last checked October 28, 2026
  1. Noureddin M, et al. Weekly pemvidutide versus placebo for MASH (IMPACT): 24-week results of a phase 2b study. Lancet 2025;406:2644-2655. PMID 41237796. Read October 28, 2026.
  2. ClinicalTrials.gov NCT07795164 (PERFORMA). Read October 28, 2026.
  3. ClinicalTrials.gov NCT07009860 (RESTORE TRIAL: Study of the Efficacy and Safety of Pemvidutide in the Treatment of Alcohol-Associated Liver Disease (ALD)). Read October 28, 2026.
  4. ClinicalTrials.gov NCT05989711 (IMPACT). Read October 28, 2026.

Petrelintide also ZP8396

Phase 3 Zealand Pharma with Roche

What it is
Long-acting human amylin analogue. Target: Amylin receptors. A weekly amylin copy designed for gentler stomach side effects.
For
Obesity; Obesity with type 2 diabetes
Phase
Roche started three phase 3 trials (ZUPREME-3, -4 and a third) on September 30, 202623
Key trials
NCT06662539 (ZUPREME) NCT07843498 (ZUPREME-3) NCT07843485 (ZUPREME-4)
Last readout
September 29, 2026. ZUPREME 1 (Lancet Diabetes Endocrinol): 7.9% to 9.8% weight loss across doses against 1.7% on placebo at 28 weeks; the top three doses performed about the same1
Next milestone
Expected October 20, 2028. Primary completion of ZUPREME-4 (obesity with type 2 diabetes)3

In plain words. Petrelintide is another weekly copy of the fullness hormone amylin. A mid-size trial showed steady weight loss with mostly mild nausea, and the biggest trials started in autumn 2026.

The science. Petrelintide is a human amylin analogue for weekly dosing. In ZUPREME 1, weight loss at the 28-week primary endpoint was similar across the three highest doses, and nausea, mostly mild and during dose escalation, was the main adverse event. Roche, which co-develops it with Zealand, started phase 3 trials in September 2026.123

Read the encyclopedia entry

Sources (4) · last checked October 28, 2026
  1. Garvey WT, et al. Petrelintide, a human amylin analogue for the treatment of obesity (ZUPREME 1): a phase 2 trial. Lancet Diabetes Endocrinol 2026. PMID 42810355. Read October 28, 2026.
  2. ClinicalTrials.gov NCT07843498 (ZUPREME-3). Read October 28, 2026.
  3. ClinicalTrials.gov NCT07843485 (ZUPREME-4). Read October 28, 2026.
  4. ClinicalTrials.gov NCT06662539 (ZUPREME). Read October 28, 2026.

Retatrutide also LY3437943

Phase 3 Eli Lilly

What it is
GIP, GLP-1 and glucagon receptor triple agonist. Target: GIP, GLP-1 and glucagon receptors. One peptide that activates three hormone receptors involved in appetite, insulin and energy use.
For
Obesity; Obstructive sleep apnoea; Knee osteoarthritis pain; Type 2 diabetes
Phase
Phase 3 complete for the first filings; Lilly plans a US Biologics License Application in the first quarter of 2027. Not approved; Lilly says it cannot legally be sold for human use32
Key trials
NCT05929066 (TRIUMPH-1) NCT05882045 (TRIUMPH-3) NCT06297603 NCT07629401 NCT06260722
Last readout
October 28, 2026. TRANSCEND-T2D-2 (Lilly topline, not yet published): HbA1c fell 2.2 points on 9 mg and 12 mg against 1.8 on semaglutide 2 mg, and weight 19.5% and 20.9% against 9.4%, at 80 weeks (1,298 adults with type 2 diabetes)9
Next milestone
Expected first quarter of 2027. Planned US submission for obesity, sleep apnoea and knee osteoarthritis pain2

In plain words. Retatrutide is an experimental weekly injection that copies three hormones at once. Together they cut hunger and change how the body uses energy, and in a large trial people lost about a quarter of their weight. It is not approved, and Lilly says it cannot legally be sold for human use.

The science. Retatrutide is a single peptide agonist of the GIP, GLP-1 and glucagon receptors. In TRIUMPH-1, an 80-week phase 3 trial, it met co-primary endpoints for body weight, knee osteoarthritis pain and the apnoea-hypopnoea index; gastrointestinal events were the most common adverse effects. Lilly plans to submit for US approval in the first quarter of 2027 and runs a single-patient expanded-access programme before then.1267

Read the encyclopedia entry

Sources (9) · last checked November 3, 2026
  1. Jastreboff AM, et al. Retatrutide, a Triple Hormone Receptor Agonist, for Treatment of Obesity. N Engl J Med 2026 (TRIUMPH-1). PMID 42814954. Read October 28, 2026.
  2. Eli Lilly: second-quarter 2026 financial results (August 5, 2026): BLA submission planned in the first quarter of 2027 (the company's own statement). Dated August 5, 2026. Read October 28, 2026.
  3. ClinicalTrials.gov NCT05929066 (TRIUMPH-1). Read October 28, 2026.
  4. ClinicalTrials.gov NCT05882045 (TRIUMPH-3). Read October 28, 2026.
  5. ClinicalTrials.gov NCT06297603 (Effect of Retatrutide Compared With Placebo in Participants With Type 2 Diabetes and Moderate or Severe Renal Impairment, With Inadequate Glycemic Control on Basal Insulin, With or Without Metformin and/or SGLT2 Inhibitor (TRANSCEND-T2D-3)). Read October 28, 2026.
  6. ClinicalTrials.gov NCT07629401 (Pre-approval Expanded Access of Retatrutide (LY3437943)). Read October 28, 2026.
  7. Eli Lilly: retatrutide delivered powerful weight loss in pivotal phase 3 obesity trial (May 21, 2026) (the company's own statement). Dated May 21, 2026. Read October 28, 2026.
  8. ClinicalTrials.gov NCT06260722 (TRANSCEND-T2D-2). Read November 3, 2026.
  9. Eli Lilly: retatrutide delivered greater A1C reduction and more than double the weight loss of Ozempic's highest approved dose in head-to-head trial (October 28, 2026) (the company's own statement). Dated October 28, 2026. Read November 3, 2026.

Ribupatide also HRS9531

Phase 3 Jiangsu Hengrui (trials registered by Fujian Shengdi Pharmaceutical)

What it is
GLP-1 and GIP receptor dual agonist. Target: GLP-1 and GIP receptors. Weekly incretin dual agonist; an oral tablet form is also in phase 3.
For
Obesity; Type 2 diabetes; Obstructive sleep apnoea; Atherosclerotic cardiovascular disease
Phase
Phase 3 programme in China, including an oral tablet trial started July 202623
Key trials
NCT06396429 NCT06994650 NCT07670884
Last readout
September 20, 2026. First-in-human study (Diabetes Obes Metab): after four weekly doses, weight fell 6.7% to 9.6% against 1.4% on placebo1
Next milestone
Expected December 2026. Primary completion of the phase 3 trial in sleep apnoea with obesity3

In plain words. Ribupatide is a weekly injection from China that copies the hormones GLP-1 and GIP to help with weight and blood sugar. A tablet form is also being tested.

The science. Ribupatide (HRS9531) is a dual GLP-1/GIP receptor agonist whose mean half-life in its first-in-human study was 7 to 8 days. A placebo-controlled phase 3 obesity trial in China reached primary completion in July 2025. Further phase 3 trials cover sleep apnoea and an oral tablet formulation.124

Read the encyclopedia entry

Sources (4) · last checked October 28, 2026
  1. He K, et al. Preclinical and First-In-Human Evaluation of Ribupatide (HRS9531), a Dual GLP-1/GIP Receptor Agonist. Diabetes Obes Metab 2026. PMID 42764407. Read October 28, 2026.
  2. ClinicalTrials.gov NCT06396429 (To Compare the Efficacy and Safety of HRS9531 and Placebo in Subjects With Overweight or Obese). Read October 28, 2026.
  3. ClinicalTrials.gov NCT06994650 (A Multicenter, Randomized, Double-blind, Placebo-controlled Phase III Clinical Study to Evaluate the Efficacy and Safety of HRS9531 Injection in Subjects With Obstructive Sleep Apnea (OSA) and Obesity Who Are on Positive Airway Pressure Ventilation (PAP) Therapy). Read October 28, 2026.
  4. ClinicalTrials.gov NCT07670884 (A Clinical Study to Evaluate the Efficacy and Safety of HRS9531 Tablets in Overweight or Obese Subjects). Read October 28, 2026.

Survodutide also BI 456906

Phase 3 Boehringer Ingelheim (licensed from Zealand Pharma)

What it is
Glucagon and GLP-1 receptor dual agonist. Target: Glucagon and GLP-1 receptors. Pairs GLP-1 satiety with glucagon-driven energy use and liver-fat loss.
For
Obesity; Type 2 diabetes with obesity; MASH (fatty liver disease with inflammation)
Phase
Phase 3 programme SYNCHRONIZE (obesity) and LIVERAGE (MASH)35
Key trials
NCT06066515 (SYNCHRONIZE™-1) NCT06066528 (SYNCHRONIZE™-2) NCT06077864 NCT07754461
Last readout
October 1, 2026. SYNCHRONIZE-2 (NEJM): weight changed -8.2% and -9.8% on the two doses against -3.9% on placebo at 76 weeks1
Next milestone
Expected January 17, 2028. Primary completion of a new phase 3 trial in type 2 diabetes6

In plain words. Survodutide is a weekly injection being tested for weight loss and fatty liver disease. It copies two hormones: one that makes you feel full and one that acts on how the body and liver use energy. Its large trials have reported, but it is not approved anywhere.

The science. Survodutide is a dual agonist of the glucagon and GLP-1 receptors. SYNCHRONIZE-1 (obesity without diabetes) and SYNCHRONIZE-2 (with type 2 diabetes) met their weight endpoints over 76 weeks, with gastrointestinal adverse events in most participants on the drug. The SYNCHRONIZE-CVOT cardiovascular safety trial reached primary completion in June 2026, and LIVERAGE trials test it in MASH.215

Read the encyclopedia entry

Sources (6) · last checked October 28, 2026
  1. Wharton S, et al. Survodutide Once Weekly in Adults with Obesity and Type 2 Diabetes. N Engl J Med 2026 (SYNCHRONIZE-2). PMID 42820639. Read October 28, 2026.
  2. le Roux CW, et al. Survodutide Once Weekly for the Treatment of Adults with Obesity. N Engl J Med 2026;395:776-787 (SYNCHRONIZE-1). PMID 42253238. Read October 28, 2026.
  3. ClinicalTrials.gov NCT06066528 (SYNCHRONIZE™-2). Read October 28, 2026.
  4. ClinicalTrials.gov NCT06066515 (SYNCHRONIZE™-1). Read October 28, 2026.
  5. ClinicalTrials.gov NCT06077864 (A Study to Test the Effect of Survodutide (BI 456906) on Cardiovascular Safety in People With Overweight or Obesity (SYNCHRONIZE™ - CVOT)). Read October 28, 2026.
  6. ClinicalTrials.gov NCT07754461 (A Study to Test Whether Survodutide Helps People With Type 2 Diabetes Control Their Blood Sugar). Read October 28, 2026.

UBT251

Phase 3 The United Bio-Technology (Hengqin) in China; Novo Nordisk runs trials outside China

What it is
GLP-1, GIP and glucagon receptor triple agonist. Target: GLP-1, GIP and glucagon receptors. A weekly triple agonist in the retatrutide class.
For
Obesity; Type 2 diabetes; Obstructive sleep apnoea
Phase
Phase 3 in China (UNIGUIDE, UNISHAPE); Novo Nordisk phase 2 elsewhere35
Key trials
NCT07659574 (UNIGUIDE-1) NCT07648225 NCT07668388
Last readout
October 8, 2026. Phase 2 in obesity (Cell Metab): weight fell 13.6% to 19.7% against 2.0% on placebo at 24 weeks1
Next milestone
Expected September 24, 2027. Primary completion of UNIGUIDE-1 in type 2 diabetes3

In plain words. UBT251 copies three hormones at once, like retatrutide. A Chinese company is testing it in large trials, and Novo Nordisk is testing it elsewhere. Mid-size trials showed large weight loss in six months.

The science. UBT251 is a triple agonist of the GLP-1, GIP and glucagon receptors. Two 24-week phase 2 trials published in Cell Metabolism in October 2026 reported weight reduction against placebo in obesity and HbA1c reduction against placebo and semaglutide in type 2 diabetes. Phase 3 trials run in China and a Novo Nordisk phase 2 elsewhere.125

Read the encyclopedia entry

Sources (5) · last checked October 28, 2026
  1. Zhou Z, et al. UBT251, a novel triple GLP-1, GIP, and glucagon receptor agonist, in adults with overweight or obesity: a phase 2 trial. Cell Metab 2026. PMID 42843337. Read October 28, 2026.
  2. Zhou Z, et al. UBT251 in adults with type 2 diabetes: a multicenter, randomized phase 2 trial. Cell Metab 2026. PMID 42933400. Read October 28, 2026.
  3. ClinicalTrials.gov NCT07659574 (UNIGUIDE-1). Read October 28, 2026.
  4. ClinicalTrials.gov NCT07648225 (UBT251 Injection Phase Ⅲ Study (Overweight or Obesity)). Read October 28, 2026.
  5. ClinicalTrials.gov NCT07668388 (A Research Study Comparing How Well Different Doses of the Medicine UBT251 Lower Blood Sugar in People With Type 2 Diabetes). Read October 28, 2026.

VK2735

Phase 3 Viking Therapeutics

What it is
GLP-1 and GIP receptor dual agonist. Target: GLP-1 and GIP receptors. Incretin dual agonist given as a weekly injection or a daily tablet.
For
Obesity; Obesity with type 2 diabetes
Phase
VANQUISH (injection) phase 3 enrolled; Viking says the SUNRISE (oral) phase 3 trials began in October 2026245
Key trials
NCT07104500 (VANQUISH 1) NCT07104383 NCT07868835
Last readout
September 22, 2026. Maintenance study (Viking topline, not yet published): 16% to 19% weight loss after 21 weeks of weekly injections; monthly maintenance doses kept 82% to 90% of it at week 33, against 61% on placebo5
Next milestone
Expected July 1, 2027. Primary completion of VANQUISH 12

In plain words. VK2735 is a weight-loss medicine that copies the gut hormones GLP-1 and GIP. It is being tested as a weekly injection and as a daily pill.

The science. VK2735 is a dual agonist of the GLP-1 and GIP receptors. In the 13-week VENTURE phase 2 trial all subcutaneous doses reduced body weight, with mainly gastrointestinal adverse events that became less frequent after titration. VANQUISH 1 and 2 test the injection in phase 3; SUNRISE 1 tests the tablet.124

Read the encyclopedia entry

Sources (5) · last checked November 3, 2026
  1. Bays HE, et al. Weekly Subcutaneous VK2735, a GIP/GLP-1 Receptor Dual Agonist, for Weight Management: Phase 2 VENTURE. Obesity 2026. PMID 41508550. Read October 28, 2026.
  2. ClinicalTrials.gov NCT07104500 (VANQUISH 1). Read October 28, 2026.
  3. ClinicalTrials.gov NCT07104383 (VK2735 for Weight Management Type 2 Diabetes Phase 3 (VANQUISH 2)). Read October 28, 2026.
  4. ClinicalTrials.gov NCT07868835 (Oral VK2735 for Weight Management Phase 3 (SUNRISE 1)). Read October 28, 2026.
  5. Viking Therapeutics: third quarter 2026 financial results and corporate update (Form 8-K exhibit, October 28, 2026) (the company's securities filing). Dated October 28, 2026. Read November 3, 2026.

Vosoritide (hypochondroplasia) also Voxzogo, BMN 111

Phase 3 BioMarin

What it is
C-type natriuretic peptide analogue. Target: NPR-B. Counteracts the FGFR3 growth-plate brake shared by achondroplasia and hypochondroplasia.
For
Hypochondroplasia (phase 3; new indication); Achondroplasia (approved 2021)
Phase
New indication in phase 3; vosoritide itself has been approved for achondroplasia since 20212
Key trials
NCT06455059 (CANOPY-HCH-3) NCT07073014 (CANOPY-HCH-EXT) NCT07126262
Last readout
September 9, 2026. CANOPY-HCH-3 (NEJM Evidence): yearly growth 2.33 cm faster than placebo after 52 weeks in 81 children1
Next milestone
Expected June 30, 2028. Primary completion of the phase 2 trial in children under 3 years4

In plain words. Hypochondroplasia is a milder cousin of achondroplasia caused by changes in the same gene. Vosoritide, a daily injection already used for achondroplasia, helped children with hypochondroplasia grow faster in a one-year trial. It is not approved for this condition.

The science. Vosoritide is a C-type natriuretic peptide analogue that works against overactive FGFR3 signalling at the growth plate. In the CANOPY-HCH-3 phase 3 trial annualised growth velocity rose by 2.33 cm a year more than on placebo at 52 weeks, with no grade 3 or higher adverse events. Effects on adult height are unknown; an open-label extension runs to 2044.123

Read the encyclopedia entry

Sources (4) · last checked October 28, 2026
  1. Dauber A, et al. A Phase 3 Trial of Vosoritide in Children with Hypochondroplasia. NEJM Evid 2026. PMID 42713641. Read October 28, 2026.
  2. ClinicalTrials.gov NCT06455059 (CANOPY-HCH-3). Read October 28, 2026.
  3. ClinicalTrials.gov NCT07073014 (CANOPY-HCH-EXT). Read October 28, 2026.
  4. ClinicalTrials.gov NCT07126262 (A Study of Vosoritide Versus Placebo in Children With Hypochondroplasia Aged 0 to < 36 Months). Read October 28, 2026.

Phase 2 (4)

Mid-size trials that test whether a drug works and at what dose. Some are registered as phase 1/2.

Efinopegdutide also MK-6024, HM12525A

Phase 2 Merck (MSD)

What it is
GLP-1 and glucagon receptor dual agonist. Target: GLP-1 and glucagon receptors. Long-acting dual agonist aimed at liver fat.
For
MASH; Compensated MASH cirrhosis
Phase
Phase 2b in MASH completed December 2025; no phase 3 registered when read1
Key trials
NCT05877547 NCT06465186
Last readout
December 29, 2025. Phase 2b in precirrhotic MASH reached primary completion; no results posted on the registry when read1
Next milestone
No date announced. No phase 3 trial registered (registry search)3

In plain words. Efinopegdutide is a weekly injection being tested for fatty liver disease with inflammation. It copies two hormones that act on how the liver handles fat. Its main mid-stage trial has finished, and results are awaited.

The science. Efinopegdutide (MK-6024) is a GLP-1 and glucagon receptor dual agonist. A 381-participant phase 2b trial in precirrhotic MASH reached primary completion in December 2025 and a trial in compensated cirrhosis in August 2026. No phase 3 trial was registered when the registry was read.123

Read the encyclopedia entry

Sources (3) · last checked October 28, 2026
  1. ClinicalTrials.gov NCT05877547 (A Clinical Study of Efinopegdutide in Participants With Precirrhotic Nonalcoholic Steatohepatitis (NASH) (MK-6024-013)). Read October 28, 2026.
  2. ClinicalTrials.gov NCT06465186 (A Clinical Study of Efinopegdutide in People With Compensated Cirrhosis Due to Steatohepatitis (MK-6024-017)). Read October 28, 2026.
  3. ClinicalTrials.gov search for efinopegdutide (read October 28, 2026): no phase 3 study. Read October 28, 2026.

Lutetium Lu 177 FAP-2286 also 177Lu-FAP-2286

Phase 2 Novartis

What it is
Cyclic peptide radioligand. Target: Fibroblast activation protein (FAP). Delivers lutetium-177 to cancer-associated fibroblasts in tumour tissue.
For
Advanced solid tumours
Phase
LuMIERE, registered as phase 1/21
Key trials
NCT04939610 (LuMIERE)
Last readout
No results reported yet in the sources read.
Next milestone
Expected December 31, 2027. Primary completion of LuMIERE1

In plain words. Many tumours are surrounded by support cells that display a protein called FAP. This radioactive drug homes in on FAP to irradiate the tumour from its surroundings. It is in early testing across several cancers.

The science. FAP-2286 is a fibroblast activation protein-binding peptide used as a radioligand. LuMIERE is a phase 1/2 study of the lutetium-177 form in advanced solid tumours, with gallium-68 FAP-2286 imaging, examining safety, dosimetry and preliminary activity.1

Sources (1) · last checked October 28, 2026
  1. ClinicalTrials.gov NCT04939610 (LuMIERE). Read October 28, 2026.

PL-5 also antimicrobial peptide PL-5 spray

Phase 2 Jiangsu ProteLight Pharmaceutical & Biotechnology

What it is
Antimicrobial peptide. Target: Bacterial membranes. A topical spray of a membrane-active antimicrobial peptide.
For
Mild infections of diabetic foot ulcers
Phase
Phase 2, placebo-controlled1
Key trials
NCT06189638 (PL-5)
Last readout
No results reported yet in the sources read.
Next milestone
Expected April 30, 2027. Primary completion of the phase 2 diabetic foot ulcer trial1

In plain words. PL-5 is a spray made from a peptide that kills bacteria. It is being tested on mildly infected foot ulcers in people with diabetes.

The science. PL-5 is an antimicrobial peptide formulated as a topical spray, tested against placebo in a 90-patient phase 2 trial in mild diabetic foot ulcer infection. An earlier topical antimicrobial peptide, pexiganan, matched oral ofloxacin in one of two phase 3 trials in the same condition but never reached approval.12

Sources (2) · last checked October 28, 2026
  1. ClinicalTrials.gov NCT06189638 (PL-5). Read October 28, 2026.
  2. Lipsky BA, et al. Topical versus systemic antimicrobial therapy for treating mildly infected diabetic foot ulcers: a randomized trial of pexiganan cream. Clin Infect Dis 2008. PMID 18990064. Read October 28, 2026.

Zelenectide pevedotin also BT8009

Phase 2 Bicycle Therapeutics

What it is
Bicyclic peptide-drug conjugate. Target: Nectin-4. A small constrained peptide that binds Nectin-4 on tumours and releases the toxin MMAE.
For
Urothelial cancer; Breast cancer; Non-small-cell lung cancer with NECTIN4 amplification
Phase
Duravelo-2 in urothelial cancer and further phase 2 trials1
Key trials
NCT06225596 NCT06840483 NCT06933329
Last readout
No results reported yet in the sources read.
Next milestone
Expected March 2028. Primary completion of Duravelo-2 (urothelial cancer)1

In plain words. Zelenectide pevedotin is a tiny ring-shaped peptide that finds a protein called Nectin-4 on some cancers and delivers a cell-killing drug to it. Because it is much smaller than an antibody, its makers hope it reaches into tumours better.

The science. Zelenectide pevedotin (BT8009) is a bicyclic peptide that binds Nectin-4, conjugated to monomethyl auristatin E through a cleavable linker. It is designed to improve on Nectin-4 antibody-drug conjugates such as enfortumab vedotin, with better tumour penetration and less systemic toxicity, though a 2025 review questions the control arms of its trials. Duravelo-2 tests it in urothelial cancer.451

Read the encyclopedia entry

Sources (5) · last checked October 28, 2026
  1. ClinicalTrials.gov NCT06225596 (Study BT8009-230 in Participants With Locally Advanced or Metastatic Urothelial Cancer (Duravelo-2)). Read October 28, 2026.
  2. ClinicalTrials.gov NCT06840483 (Study of Zelenectide Pevedotin in Participants With Advanced Breast Cancer). Read October 28, 2026.
  3. ClinicalTrials.gov NCT06933329 (Zelenectide Pevedotin in NECTIN4 Amplified Advanced or Metastatic Non-small Cell Lung Cancer). Read October 28, 2026.
  4. Cigliola A, et al. Zelenectide pevedotin (BT-8009): a bicyclic peptide toxin conjugate targeting nectin-4 for the treatment of bladder cancer. Expert Opin Investig Drugs 2025. PMID 40401457. Read October 28, 2026.
  5. Tweed JA, et al. The validation and clinical bioanalysis of the Bicycle Toxin Conjugate zelenectide pevedotin in human plasma. Bioanalysis 2025. PMID 39829185. Read October 28, 2026.

Phase 1 (2)

First studies in people, mostly about safety and how the body handles the drug.

PN-881

Phase 1 Protagonist Therapeutics

What it is
Oral peptide antagonist. Target: IL-17A and IL-17F. Blocks the IL-17 signals that drive psoriasis, taken by mouth.
For
Psoriasis (planned phase 2); Psoriatic arthritis, hidradenitis suppurativa, axial spondyloarthritis (planned)
Phase
Phase 1 in healthy volunteers completed July 2026; the company plans a phase 2 psoriasis programme from early 2027213
Key trials
NCT07153146
Last readout
September 17, 2025. Preclinical data at EADV 2025: activity against all three IL-17 dimer forms (company release)1
Next milestone
Expected first quarter of 2027. Start of a phase 2 psoriasis programme, on the strength of the phase 1 drug-level data, as the company expects3

In plain words. PN-881 comes from the company behind icotrokinra and aims to block another psoriasis signal, IL-17, with a pill instead of an injection. It has finished its first safety study in healthy volunteers.

The science. PN-881 is an oral peptide targeting the IL-17 pathway that binds IL-17A and IL-17F; preclinically it was active against all three IL-17 dimer forms, according to the company. A single- and multiple-ascending-dose phase 1 reached primary completion in July 2026, and a dose-ranging psoriasis trial is planned.12

Sources (3) · last checked October 28, 2026
  1. Protagonist Therapeutics: icotrokinra clinical data and PN-881 preclinical data at EADV 2025 (September 17, 2025) (the company's own statement). Dated September 17, 2025. Read October 28, 2026.
  2. ClinicalTrials.gov NCT07153146 (Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of PN-881 in Healthy Subjects.). Read October 28, 2026.
  3. Protagonist: second quarter 2026 financial results and corporate update (August 5, 2026) (the company's own statement). Dated August 5, 2026. Read October 28, 2026.

Zosurabalpin also RG6006, RO7223280

Phase 1 Roche

What it is
Tethered macrocyclic peptide antibiotic. Target: LptB2FGC lipopolysaccharide transporter. Traps lipopolysaccharide inside the bacterium so it cannot build its outer membrane.
For
Carbapenem-resistant Acinetobacter baumannii infections
Phase
Phase 1 studies in healthy volunteers and critically ill patients completed; no later-phase trial registered when read23
Key trials
NCT04605718 NCT05614895
Last readout
January 3, 2024. Nature 2024: a new antibiotic class that blocks lipopolysaccharide transport and treated drug-resistant A. baumannii in mice1
Next milestone
No date announced. No later-phase trial registered (registry search)5

In plain words. Some hospital germs, like carbapenem-resistant Acinetobacter, resist almost every antibiotic. Zosurabalpin is a ring-shaped peptide antibiotic that stops these bacteria from building their outer shell. It worked in mice and has been tested for safety in people.

The science. Zosurabalpin is a tethered macrocyclic peptide that inhibits the LptB2FGC complex and blocks transport of lipopolysaccharide to the outer membrane of Acinetobacter baumannii. Its discoverers note that no new antibiotic class active against A. baumannii had reached patients in over 50 years. Two phase 1 studies are complete, and 2026 laboratory surveys report activity against global carbapenem-resistant isolates.1234

Sources (5) · last checked October 28, 2026
  1. Zampaloni C, et al. A novel antibiotic class targeting the lipopolysaccharide transporter. Nature 2024;625:566-571. PMID 38172634. Read October 28, 2026.
  2. ClinicalTrials.gov NCT04605718 (A Study To Investigate The Safety, Tolerability And Pharmacokinetics (PK) Of RO7223280 Following Intravenous Administration In Healthy Participants). Read October 28, 2026.
  3. ClinicalTrials.gov NCT05614895 (A Study to Investigate the Pharmacokinetics of RO7223280 in Critically Ill Participants With Bacterial Infections). Read October 28, 2026.
  4. Mancini S, et al. In vitro activity of zosurabalpin against a global set of carbapenem-resistant Acinetobacter baumannii clinical isolates. Antimicrob Agents Chemother 2026. PMID 42747471. Read October 28, 2026.
  5. ClinicalTrials.gov search for zosurabalpin, RG6006 and RO7223280 (read October 28, 2026): two phase 1 studies, no later phase. Read October 28, 2026.

Announced by the company, no registered trial (3)

Made public by the developing company, in its own release or a securities filing, with no trial record on ClinicalTrials.gov. Most are in animal studies; a company may also say a first human study has begun before any registry record appears. Everything in these rows is the company's own account, not independent results.

Searched October 28, 2026. Company releases and SEC filings (Ascletis, Protagonist, Viking, Zealand, Pfizer with the former Metsera molecules, Novo Nordisk, Hengrui, Innovent, Boehringer Ingelheim with Gubra, Structure, Rivus, Onconic, OPKO and Entera), ObesityWeek 2026, EASD 2026 and AASLD announcements, licensing-deal news, and Reuters, Endpoints, Fierce Biotech, STAT and Bloomberg coverage; every candidate was then looked up on ClinicalTrials.gov. Three peptides met the bar: made public by their developer, with no trial record on ClinicalTrials.gov.

Left out: candidates the companies describe as small molecules (Rivus's RV-8451, Ascletis's ASC39 and the oral molecules Zealand licensed from OTR Therapeutics); candidates whose company does not say whether they are peptides (Hengrui's HRS-1596, licensed to Novo Nordisk, and Onconic's OCN-501); and announced peptides that already have registered trials (Boehringer Ingelheim's BI 3034701, Gubra's GUB-UCN2 and Ascletis's ASC35 and ASC36), which belong in a clinical phase rather than here.

ASC37 also ASC37o, ASC37i

Announced by the company, no registered trial Ascletis Pharma

Announced, not yet in a registered trial. Source: the company's own release, October 19, 2026. Nothing here has been checked independently.

What it is
Triple-agonist peptide (oral tablet and long-acting injection). Target: GLP-1, GIP and glucagon receptors. Activates all three receptors at once; designed for once-weekly dosing by mouth.
For
Obesity (planned)
Phase
Announced by Ascletis on October 19, 2026 with monkey data; the company expects to submit an FDA investigational new drug application for the ASC37o tablet in the fourth quarter of 2026, and for tablets that pair ASC37 with its amylin agonist ASC36. No ASC37 trial is registered on ClinicalTrials.gov12
Key trials
None registered.
Last readout
October 19, 2026. Company-reported monkey data: ASC37o tablets reached a half-life of up to about 79 hours (about 3.3 days) and oral bioavailability of 3.5% to 7.9% at steady state1
Next milestone
Expected fourth quarter of 2026. FDA investigational new drug submission for the ASC37o tablet, as the company expects1

In plain words. ASC37 is a lab-made peptide from Ascletis meant to act on three appetite and blood-sugar hormone receptors at once, taken as a tablet once a week. So far it has been tested only in animals, and the company has not yet asked to start human trials.

The science. Ascletis describes ASC37 as a GLP-1R/GIPR/GCGR triple peptide agonist, made as a once-weekly oral tablet (ASC37o) and as a once-monthly to once-quarterly subcutaneous injection (ASC37i). In non-human primates at steady state, ASC37o reached a half-life of up to 79 hours and oral bioavailability of 3.5% to 7.9%, according to the company. The company also plans a fixed-dose tablet of ASC37 with its amylin receptor agonist ASC36. These are company-reported pre-clinical figures, not peer-reviewed results.1

Sources (2) · last checked October 28, 2026
  1. Ascletis: positive preclinical data for its once-weekly oral peptide pipeline for obesity (October 19, 2026) (the company's own statement). Dated October 19, 2026. Read October 28, 2026.
  2. ClinicalTrials.gov search for ASC37 (read October 28, 2026): no study found. Read October 28, 2026.

Oral long-acting PTH analog (LA-PTH) also oral LA-PTH

Announced by the company, no registered trial OPKO Health and Entera Bio

Announced, not yet in a registered trial. Source: a securities filing, February 4, 2026. Nothing here has been checked independently.

What it is
Oral parathyroid hormone analog peptide. Target: Parathyroid hormone receptor. A long-acting PTH variant from OPKO in Entera's N-Tab oral tablet, meant to replace missing parathyroid hormone.
For
Hypoparathyroidism (planned)
Phase
Announced by OPKO Health and Entera Bio on February 4, 2026, in a release Entera filed with the SEC: pre-clinical, with an FDA investigational new drug application expected in late 2026. No study of the long-acting analog is registered on ClinicalTrials.gov12
Key trials
None registered.
Last readout
December 2025. Pre-clinical pharmacokinetic and pharmacodynamic data the companies call favourable, reported without figures1
Next milestone
Expected fourth quarter of 2026. FDA investigational new drug application, as the companies expect1

In plain words. OPKO and Entera are developing a once-a-day tablet of a long-acting form of parathyroid hormone, for people whose bodies make too little of it. It has been studied only in animals so far, and the companies plan to ask FDA to start human trials in late 2026.

The science. The programme pairs OPKO's long-acting PTH variants with Entera's N-Tab oral peptide delivery platform, aiming at a once-daily tablet for hypoparathyroidism. The companies say their pre-clinical data support a single once-daily tablet at a significantly lower daily dose, without publishing figures.1

Sources (2) · last checked October 28, 2026
  1. Entera Bio Form 8-K, exhibit 99.1: OPKO Health and Entera Bio expand partnership to advance an oral long-acting PTH tablet for hypoparathyroidism (February 4, 2026) (the company's securities filing). Dated February 4, 2026. Read October 28, 2026.
  2. ClinicalTrials.gov search for hypoparathyroidism studies sponsored by Entera or OPKO (read October 28, 2026): only the earlier oral PTH(1-34) studies, none of the long-acting analog. Read October 28, 2026.

PN-477 also PN-477o, PN-477sc

Announced by the company, no registered trial Protagonist Therapeutics

Announced, not yet in a registered trial. Source: the company's own release, August 5, 2026. Nothing here has been checked independently.

What it is
Triple-agonist peptide (oral and injectable). Target: GLP-1, GIP and glucagon receptors. Activates all three receptors; engineered to stay stable when swallowed.
For
Obesity
Phase
Announced by Protagonist as a development candidate in June 2025. On August 5, 2026 the company said a phase 1 study of the injectable form had begun and a phase 1 of the oral form is expected in the first half of 2027. No PN-477 study is registered on ClinicalTrials.gov23
Key trials
None registered.
Last readout
June 30, 2025. Development candidate nominated; the company described pre-clinical effects on obesity and blood sugar in mice, dogs and monkeys without publishing figures1
Next milestone
Expected first half of 2027. Start of a phase 1 study of oral PN-477, as the company expects2

In plain words. PN-477 is a peptide from Protagonist, the company behind the psoriasis pill icotrokinra, built to act on three gut-hormone receptors that control appetite and blood sugar. The company says a first human study of the injected version has started and a pill version will follow, but no trial record is public on ClinicalTrials.gov yet.

The science. Protagonist nominated PN-477 in June 2025 as a GLP-1R/GIPR/GCGR triple agonist peptide engineered to be orally stable, for once-daily oral (PN-477o) and once-weekly subcutaneous (PN-477sc) use. The company reported in vitro activity at all three receptors and pre-clinical work in diet-induced obese mice, normal dogs and cynomolgus monkeys, describing effects on obesity and glycaemic control without figures. In August 2026 it said a phase 1 study of PN-477sc had begun.12

Sources (3) · last checked October 28, 2026
  1. Protagonist: nomination of PN-477, an oral and injectable GLP-1R, GIPR and GCGR triple agonist peptide development candidate for obesity (June 30, 2025) (the company's own statement). Dated June 30, 2025. Read October 28, 2026.
  2. Protagonist: second quarter 2026 financial results and corporate update (August 5, 2026) (the company's own statement). Dated August 5, 2026. Read October 28, 2026.
  3. ClinicalTrials.gov search for PN-477 and for Protagonist studies started since June 2025 (read October 28, 2026): no PN-477 study found. Read October 28, 2026.

Pre-clinical, published (1)

Designed and published in a peer-reviewed paper, in cells or animals only.

GLP-1-GIP-lanifibranor conjugate also quintuple agonist

Pre-clinical, published Academic research (published in Nature)

What it is
Peptide-small-molecule conjugate. Target: GLP-1 and GIP receptors plus PPAR-alpha, -gamma and -delta. A GLP-1/GIP co-agonist peptide that carries the pan-PPAR drug lanifibranor into target cells.
For
Obesity and diabetes (mouse studies only)
Phase
Announced in a peer-reviewed paper; mouse data only, no human trial registered1
Key trials
None registered.
Last readout
April 29, 2026. In obese mice it lowered body weight, food intake and blood glucose more than GLP-1/GIP co-agonism or semaglutide1
Next milestone
No date announced. No human trial announced1

In plain words. Scientists built one molecule that hits five targets: two gut-hormone receptors on the cell surface and three fat-and-sugar switches inside the cell. In mice it beat semaglutide. It has never been given to a person.

The science. The conjugate links a GLP-1R/GIPR co-agonist peptide to lanifibranor, a pan-PPAR agonist. In obese, insulin-resistant mice it lowered body weight, food intake and blood glucose more than GLP-1R/GIPR co-agonism or semaglutide, and its effects were blunted when GLP-1R, GIPR or PPAR-delta was inhibited. It is a mouse-stage finding.1

Sources (1) · last checked October 28, 2026
  1. Liskiewicz D, et al. GLP-1R-GIPR-PPARalpha/gamma/delta quintuple agonism corrects obesity and diabetes in mice. Nature 2026;653:776-785. PMID 42056522. Read October 28, 2026.

Rumoured, not confirmed by the company (0)

Reported by a named news outlet but not confirmed by the developer. Listed only with the outlet and the date, and labelled as a rumour.

Searched October 28, 2026. Reuters, Endpoints News, Fierce Biotech, STAT and Bloomberg, for peptide molecules reported but not confirmed by their developers. None met the bar. Every report found either rested on a company's own announcement (those molecules are listed under their phase above) or did not name a specific peptide molecule.

How this tracker is kept

Every row is a record in a data file, and the page is rebuilt from it. A row's phase rests on a registry record on ClinicalTrials.gov, a regulator's document (an FDA approval list, a label on DailyMed or an agency announcement) or the developing company's own release, filing or pipeline statement. A company's statement is labelled as such, and a peer-reviewed paper replaces a topline release once it is published. Results come from peer-reviewed papers, checked against PubMed, or from the company's release when no paper exists yet. Each of the 114 trial records the rows cite is stored as read, with the date it was read.

Every row is checked again at least every 45 days; each card shows its own last-checked date, and the site's build gate fails if any row is older than that, if a phase has no registry, regulator or company source, if a cited trial has no stored record, or if a clinical phase disagrees with the row's own trial records. An announced row must rest on the company's own release or a securities filing, with its date, and list no registered trial; a published pre-clinical row on a paper or the developer; a rumoured row on a named news outlet, with its date, and it is labelled as a rumour. Announced and rumoured rows are held to the same 45-day check as every other row. The tracker names no seller and no grey-market source, and gives no doses.

Which molecules count: peptides and drugs built on peptides, including peptide conjugates, radioligands whose targeting part is a peptide or peptidomimetic, and insulins. Small molecules that act on the same receptors, such as orforglipron, are left out even when news coverage groups them with peptides. Where an older drug is being tested or newly approved for a different condition, it gets its own row for that use. The data is published as pipeline-tracker.json; corrections are welcome through the about page, and our general approach is on the methodology page.

The long list: every INN-named peptide at phase 2 or beyond

Every peptide with an international nonproprietary name that has reached phase 2 or beyond in ChEMBL, 331 molecules, with what ClinicalTrials.gov says about their active studies. Read on October 1, 2026; 97 have an active study and 78 have an entry in the encyclopedia. This list is built by machine from the two databases, so it is broader than the tracker above and less current: ChEMBL can take months to record an approval.

Dates here are registered primary completion dates: when a sponsor expects a trial's main data collection to end. They are estimates the sponsor can move, not results and not approval decisions. Download: pipeline-data.json.

An approval, when it comes, is narrow: one formulation, one dose, one condition. Elamipretide shows what that means in practice: SS-31 became a drug, and what that does not mean. The two oral peptides approved this year have their own explainers, icotrokinra and enlicitide; for the appetite science behind the obesity drugs, read peptide YY vs neuropeptide Y.

Expected in the next 90 days

Readouts registered for October 1, 2026 to December 30, 2026, earliest first; a date given only as a month counts if the month overlaps the window. 33 in all.

Registered dates that have passed

These studies' estimated completion dates are behind us and the registry has not been updated, which is worth knowing in itself.

All 331 molecules

331 of 331 shown
Most advanced active study Lead sponsorsFirst approval
abaloparatideApproved (phase 4)Phase 46February 2027 NCT03841058Hospital for Special Surgery, New York, State University of New York at Buffalo2017
abarelixApproved (phase 4)—0——2003
aclerastidePhase 3—0———
act-1 peptidePhase 3—0———
afamelanotideApproved (phase 4)Phase 31December 2025 NCT06109649Clinuvel, Inc.2014
albiglutideApproved (phase 4)—1May 31, 2026 NCT05220917Brigham and Women's Hospital2014
albuvirtidePhase 3—2July 2028 NCT07727642Shanghai Public Health Clinical Center, Shanxi Bethune Hospital—
alizulatide vixocianinePhase 2—0———
almurtidePhase 2—0———
alsactidePhase 2—0———
amilomotidePhase 2—0———
amlintidePhase 2—1October 2026 NCT07506369University Hospital, Gentofte, Copenhagen—
anamorelinPhase 3Phase 32December 31, 2026 NCT03637816M.D. Anderson Cancer Center—
anaritide acetatePhase 2—0———
anfibatidePhase 2—0———
argipressin tannatePhase 2—0———
argiprestocinPhase 2—0———
aspartocinPhase 2—0———
avexitidePhase 3Phase 31July 8, 2026 NCT06747468Amylyx Pharmaceuticals Inc.—
avorelinPhase 2—0———
azetirelinPhase 2—0———
balixafortidePhase 3Phase 11February 2027 NCT06981806Arsen Osipov—
baloramotidePhase 2—0———
betiatidePhase 2—0———
bevemipretidePhase 2—0———
bibapcitidePhase 2—0———
bofanglutidePhase 2Phase 32October 2027 NCT07628985Carnot Laboratories—
bremelanotideApproved (phase 4)Phase 21February 5, 2025 NCT06565611Palatin Technologies, Inc2019
brimapitidePhase 3—0———
bulevirtideApproved (phase 4)Phase 310November 2026 NCT07142811Vir Biotechnology, Inc., Mirum Pharmaceuticals, Inc.2020
buserelinApproved (phase 4)Phase 33November 11, 2026 NCT05050084NRG Oncology, Proton Collaborative Group—
cagrilintidePhase 3Phase 316March 1, 2027 NCT07011667Novo Nordisk A/S—
canvuparatidePhase 2Phase 31January 2028 NCT07699471MBX Biosciences—
capromab pendetideApproved (phase 4)—0——1996
capromorelinPhase 2—0———
carbetocinApproved (phase 4)Phase 414March 1, 2028 NCT07401524Sheba Medical Center, Mansoura University—
cargutocinPhase 2—0———
carperitidePhase 3—0———
cenderitidePhase 2—0———
certepetidePhase 2Phase 22September 2025 NCT05121038Anup Kasi, Qilu Pharmaceutical Co., Ltd.—
ceruletideApproved (phase 4)—0——1982
ceruletide diethylamineApproved (phase 4)—0——1982
cetrorelixApproved (phase 4)Phase 48December 2026 NCT07350317Merck Healthcare KGaA, Darmstadt, Germany, an affiliate of Merck KGaA, Darmstadt, Germany, Trust Fertility Clinic1999
cibinetidePhase 2—0———
cilengitidePhase 3—0———
codactidePhase 2—0———
copper (64cu) adarulatide tetraxetanPhase 2—0———
copper oxodotreotideApproved (phase 4)—0——2020
copper oxodotreotide cu-64Approved (phase 4)—0——2020
corticorelinPhase 3Phase 12July 24, 2022 NCT04037605Peter y. Liu, Lundquist Institute for Biomedical Innovation at Harbor-UCLA Medical Center—
corticorelin ovine triflutateApproved (phase 4)—0——1996
cotadutidePhase 2—0———
dalazatidePhase 2—0———
danegaptidePhase 3—0———
dapiglutidePhase 2Phase 21April 24, 2024 NCT05788601University Hospital, Gentofte, Copenhagen—
davalintidePhase 2—0———
davunetidePhase 2—0———
dazdotuftidePhase 3—0———
degarelixApproved (phase 4)Phase 440November 2026 NCT03951831Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins, University of Colorado, Denver2008
delmitidePhase 2—0———
demoxytocinPhase 2—0———
depreotideApproved (phase 4)—0——1999
deslorelinPhase 2—0———
desmopressinApproved (phase 4)Phase 414February 2027 NCT06337838Hospital de Clinicas de Porto Alegre, Medical University of Bialystok1978
detirelix acetatePhase 2—0———
diamfenetidePhase 2—0———
diclometidePhase 2—0———
dirucotidePhase 3—0———
disaccharide tripeptide glycerol dipalmitoylPhase 2—0———
disitertidePhase 2—0———
disomotidePhase 2—0———
dolcanatidePhase 2—0———
doreptidePhase 2—0———
dulaglutideApproved (phase 4)Phase 415October 1, 2026 NCT06257966Eli Lilly and Company, National University of Singapore2014
dumorelinPhase 2—0———
dusquetidePhase 3—0———
ebiratidePhase 2—0———
ecallantideApproved (phase 4)—0——2009
ecnoglutidePhase 3Phase 37November 30, 2026 NCT07553299Hangzhou Sciwind Biosciences Co., Ltd., Verdiva Bio Dev Limited—
ederimotidePhase 2—0———
edotreotidePhase 3Phase 34June 2027 NCT04919226ITM Solucin GmbH, Grupo Espanol de Tumores Neuroendocrinos—
edotreotide gallium ga-68Approved (phase 4)—0——2016
edotreotide yttriumPhase 2—0———
edotreotide yttrium y-90Phase 2—0———
edratidePhase 2—0———
efinopegdutidePhase 2—0———
efmedaglutide alfaPhase 2—0———
efocipegtrutidePhase 2—0———
efpeglenatidePhase 3—0———
efsubaglutide alfaPhase 2Phase 46November 30, 2026 NCT07163650Shanghai Yinnuo Pharmaceutical Technology Co., Ltd., The Affiliated Nanjing Drum Tower Hospital of Nanjing University Medical School—
elamipretidePhase 3Phase 43August 2027 NCT06373731Stealth BioTherapeutics Inc., David Marcinek—
eloralintidePhase 2Phase 315March 2027 NCT07215559Eli Lilly and Company—
elpamotidePhase 2—0———
elsiglutidePhase 2—0———
emideltidePhase 2—0———
enavermotidePhase 2—0———
eneboparatidePhase 2Phase 31November 15, 2024 NCT05778071Alexion Pharmaceuticals, Inc.—
enfuvirtideApproved (phase 4)—0——2003
enlicitidePhase 3Phase 38October 12, 2027 NCT07614984Merck Sharp & Dohme LLC—
enlicitide chloridePhase 2—0———
enlicitide decanoatePhase 3Phase 37October 12, 2027 NCT07614984Merck Sharp & Dohme LLC—
ensereptidePhase 2—0———
eptifibatideApproved (phase 4)Phase 31September 30, 2029 NCT07347626Xinqiao Hospital of Chongqing1998
etarfolatidePhase 2—0———
etelcalcetideApproved (phase 4)Phase 33June 30, 2027 NCT03969329Amgen2016
etimumotidePhase 2—0———
examorelinPhase 2—0———
exenatideApproved (phase 4)Phase 48December 31, 2025 NCT05482789Seattle Children's Hospital, Maisa N. Feghali, MD2005
felypressinPhase 2—0———
fequesetidePhase 2—0———
fertirelinPhase 2—0———
fexapotidePhase 3—0———
fexapotide triflutatePhase 3—0———
fluciclatidePhase 2—0———
fluciclatide f 18Phase 2—0———
froniglutidePhase 2—0———
gallium (68ga) rofapitide tetraxetanPhase 2—0———
gallium oxodotreotideApproved (phase 4)Phase 26November 2, 2026 NCT05691465OHSU Knight Cancer Institute, Mayo Clinic2016
gallium rofapitidexetanPhase 2—0———
ganipatidePhase 2—0———
ganirelixApproved (phase 4)Phase 44October 31, 2026 NCT06745466University of Delaware1999
gersizangitidePhase 2—0———
ghrelinPhase 3Phase 25December 16, 2007 NCT03338387Charles University, Czech Republic—
giractidePhase 2—0———
glepaglutidePhase 3Phase 32September 18, 2028 NCT07228403Zealand Pharma—
glisentidePhase 2—0———
glucagon-like peptide iiPhase 3—0———
gonadorelinApproved (phase 4)Phase 34December 2028 NCT04390646Nelly Pitteloud1982
goralatidePhase 2—0———
goserelinApproved (phase 4)Phase 469November 2026 NCT05607004City of Hope Medical Center, Fudan University1989
gozetotideApproved (phase 4)Phase 312December 30, 2026 NCT06145633Jonsson Comprehensive Cancer Center, Fred Hutchinson Cancer Center2020
gozetotide alf-18Phase 3—0———
hepalatidePhase 2Phase 32June 2027 NCT07309380Shanghai HEP Pharmaceutical Co., Ltd.—
histrelinApproved (phase 4)Phase 35November 11, 2026 NCT05050084NRG Oncology, VA Office of Research and Development1991
human c-peptidePhase 2—0———
icrocaptidePhase 2—0———
ilatreotidePhase 2—0———
imsamotidePhase 2—0———
indium in 111 satumomab pendetideApproved (phase 4)—0——1991
indium pentetreotideApproved (phase 4)—0——1994
invopressinPhase 2—0———
iodine i124 evuzamitidePhase 2—0———
ipamorelinPhase 2—0———
irucalantidePhase 2—0———
iturelixPhase 2—0———
lagatidePhase 2—0———
lancovutidePhase 2—0———
lanreotideApproved (phase 4)Phase 48November 2026 NCT05050942Grupo Espanol de Tumores Neuroendocrinos, Antonio Fojo2007
larazotidePhase 3—0———
lead (212pb) bamzireotide navoxetanPhase 2—0———
lead (212pb) lapemelanotide zapixetanPhase 2—0———
lead bamzireotide navoxetanPhase 2—0———
lead lapemelanotide zapixetanPhase 2—0———
leconotidePhase 2—0———
lenomorelinPhase 2—0———
linaclotideApproved (phase 4)Phase 47October 2026 NCT03119584University of Florida, Sidney Kimmel Comprehensive Cancer Center at Thomas Jefferson University2012
liraglutideApproved (phase 4)Phase 430December 31, 2026 NCT03856632University of Virginia, 4Moving Biotech2009
livoletidePhase 2—0———
lixisenatideApproved (phase 4)Phase 45June 30, 2027 NCT07173712Yanbing Li, Sanofi2013
lorutengitidePhase 2—0———
lsalt peptidePhase 3Phase 21March 2027 NCT05879432Arch Biopartners Inc.—
lucicebtidePhase 2—0———
lusupultidePhase 2—0———
lutetium (177lu) tezuvotide tetraxetanPhase 2—0———
lutetium (lu177) rofapitide tetraxetanPhase 2—0———
lutetium lu 177 zadavotide guraxetanPhase 2Phase 31June 4, 2029 NCT07611110AstraZeneca—
lutetium oxodotreotideApproved (phase 4)Phase 210November 2, 2026 NCT05691465National Cancer Institute (NCI), OHSU Knight Cancer Institute2017
lutetium oxodotreotide lu-177Approved (phase 4)Phase 210November 2, 2026 NCT05691465National Cancer Institute (NCI), OHSU Knight Cancer Institute2017
lutetium rofapitidexetanPhase 2—0———
lutetium tezuvotidexetanPhase 2—0———
lutrelinPhase 2—0———
lypressinApproved (phase 4)—1June 30, 2024 NCT05266534Wael Elbanna Clinic1982
macimorelinApproved (phase 4)—0——2017
maraciclatidePhase 2—0———
maridebart cafraglutidePhase 2Phase 315January 21, 2027 NCT06858878Amgen—
marlumotidePhase 2—0———
mazdutidePhase 3Phase 416April 2027 NCT07843862West China Hospital, Tongji Hospital—
mertiatideApproved (phase 4)—0——1990
mibenratidePhase 2—0———
mifamurtideApproved (phase 4)Phase 22July 31, 2033 NCT07787429UNICANCER, Anna Raciborska2009
mifamurtide acidApproved (phase 4)—0——2009
mifomelatidePhase 2Phase 21October 2027 NCT06937177Endevica Bio—
milpocitidePhase 2—0———
modimelanotidePhase 2—0———
montirelinPhase 2—0———
motixafortideApproved (phase 4)Phase 46December 31, 2026 NCT07101445Guangzhou Gloria Biosciences Co., Ltd., Emory University2023
murabutidePhase 2—0———
nacartocinPhase 2—0———
nafarelinApproved (phase 4)Phase 43September 2027 NCT06150703Fundacion Dexeus, Assistance Publique - Hôpitaux de Paris1990
nangibotidePhase 2Phase 21May 9, 2022 NCT04055909Inotrem—
navepegritidePhase 2Phase 23August 2027 NCT06732895Ascendis Pharma A/S, Ascendis Pharma Growth Disorders A/S—
nemifitidePhase 2—0———
nerinetidePhase 3—0———
nesiritideApproved (phase 4)Phase 21December 2018 NCT02608996Oslo University Hospital2001
nisotirostidePhase 2—0———
noraramtidePhase 2—0———
norleusactidePhase 2—0———
nosiheptidePhase 2—0———
obinepitidePhase 2—0———
ociltidePhase 2—0———
octreotideApproved (phase 4)Phase 434November 2026 NCT05050942CSPC ZhongQi Pharmaceutical Technology Co., Ltd., Camurus AB1988
olatorepatidePhase 2Phase 23November 13, 2026 NCT07431086Regeneron Pharmaceuticals—
omramotidePhase 2—0———
onvitrelin ucalontidePhase 2—0———
ornipressinPhase 2—0———
orotirelinPhase 2—0———
ovemotidePhase 2—0———
oximbomotidePhase 2—0———
oxytocinApproved (phase 4)Phase 481October 2026 NCT06036004University Hospital, Basel, Switzerland, Wake Forest University Health Sciences1980
ozarelixPhase 3—0———
palopegteriparatideApproved (phase 4)Phase 34June 2027 NCT07081997Ascendis Pharma Bone Diseases A/S, Ascendis Pharma A/S2023
paluratidePhase 2—0———
pancreatic polypeptidePhase 2—1October 2026 NCT07506369University Hospital, Gentofte, Copenhagen—
pareptidePhase 2—0———
pasireotideApproved (phase 4)Phase 45October 29, 2026 NCT05928390University Hospital Heidelberg, Helsinki University Central Hospital2012
pasireotide diaspartateApproved (phase 4)Phase 21October 29, 2026 NCT05928390RECORDATI GROUP2012
peforelinPhase 2—0———
pegapamodutidePhase 2—0———
peginesatideApproved (phase 4)—0——2012
pegloprastidePhase 2—0———
pegmispotidePhase 2—0———
pegsebrenatidePhase 2—0———
pemvidutidePhase 2Phase 32September 30, 2027 NCT07009860Altimmune, Inc.—
pendetidePhase 2—0———
pentetreotideApproved (phase 4)—0——1994
pentigetidePhase 2—0———
peptide tPhase 2Phase 11November 2030 NCT07481136Javid Moslehi, MD—
peptide yy human (3-36)Phase 2—0———
petrelintidePhase 2Phase 35November 12, 2027 NCT07589686Hoffmann-La Roche—
pezadeftidePhase 2—0———
pimelautidePhase 2—0———
plecanatideApproved (phase 4)Phase 21October 18, 2027 NCT07723924Bausch Health Americas, Inc.2017
pobrolitidePhase 2—0———
posatirelinPhase 2—0———
pr1 leukemia peptide vaccinePhase 3—0———
pralmorelinPhase 2—0———
pramlintideApproved (phase 4)Early phase 13October 2026 NCT07506369Boston University, University Hospital, Gentofte, Copenhagen2005
prazarelixPhase 2—0———
protirelinApproved (phase 4)—0——1976
quazomotidePhase 2—0———
ramorelixPhase 2—0———
recanaclotidePhase 2—0———
redasemtidePhase 2—0———
relamorelinPhase 3—0———
retatrutidePhase 3Phase 311October 2026 NCT06297603Eli Lilly and Company, Hudson Biotech—
rimtoregtidePhase 2—0———
rismorelinPhase 2—0———
rolipoltidePhase 2—0———
romurtidePhase 2—0———
rotigaptidePhase 2—0———
rovatirelinPhase 3—0———
rusalatidePhase 2—0———
rusfertidePhase 3Phase 34October 28, 2027 NCT07648030Takeda, Protagonist Therapeutics, Inc.—
ruxotemitidePhase 2—0———
satoreotide tetraxetanPhase 2—0———
satoreotide trizoxetanPhase 2—0———
seglitidePhase 2—0———
selcopintidePhase 2—0———
selepressinPhase 2—0———
semaglutideApproved (phase 4)Phase 4280October 15, 2026 NCT07505303Novo Nordisk A/S, Mayo Clinic2017
semparatidePhase 2—0———
seractide acetateApproved (phase 4)—0——1978
sermorelin acetateApproved (phase 4)—0——1990
setmelanotideApproved (phase 4)Phase 45October 31, 2026 NCT06772597Rhythm Pharmaceuticals, Inc., Massachusetts General Hospital2020
sinapultidePhase 2—0———
solnatidePhase 2—0———
somatorelinApproved (phase 4)—0———
sonefpeglutidePhase 2Phase 21December 2027 NCT04775706Hanmi Pharmaceutical Company Limited—
sovatelitidePhase 3—0———
sucantomotidePhase 2—0———
sudocetaxel zendusortidePhase 2—0———
sulglicotidePhase 2—0———
survodutidePhase 3Phase 310November 30, 2027 NCT07206290Boehringer Ingelheim, University Medical Center Groningen—
svn53-67/m57-klh peptide vaccinePhase 2Phase 23March 30, 2029 NCT07169617Roswell Park Cancer Institute, National Cancer Institute (NCI)—
tabilautidePhase 2—0———
tabimorelinPhase 2—0———
talfirastidePhase 2—0———
talogreptide mesaroxetanPhase 2—0———
taltirelinPhase 2—0———
taspoglutidePhase 3—0———
tecemotidePhase 3—0———
technetium (99mtc) apcitideApproved (phase 4)—0——1998
technetium mertiatideApproved (phase 4)—0——1990
teduglutideApproved (phase 4)Phase 34February 10, 2027 NCT06973304International Centre for Diarrhoeal Disease Research, Bangladesh, Takeda2012
temurtidePhase 2—0———
teprotidePhase 2—0———
teriparatideApproved (phase 4)Phase 414December 30, 2026 NCT04589819Ditte Hansen, Massachusetts General Hospital1987
terlipressinApproved (phase 4)Phase 39May 2026 NCT06256432Noorik Biopharmaceuticals AG, Institute of Liver and Biliary Sciences, India2022
tertomotidePhase 3Phase 31January 2028 NCT05303701Samsung Pharmaceutical Co., Ltd.—
tesamorelinApproved (phase 4)Phase 23February 14, 2027 NCT07481734Massachusetts General Hospital, Johns Hopkins University2010
teverelixPhase 2Phase 22September 2027 NCT07457164Antev Ltd.—
tifuvirtidePhase 2—0———
tigapotidePhase 2—0———
tiplimotidePhase 2—0———
tirzepatideApproved (phase 4)Phase 4162October 30, 2026 NCT06861439Eli Lilly and Company, Mayo Clinic2022
tosactidePhase 2—0———
tozuleristidePhase 2—0———
tricosactidePhase 2—0———
tridecactidePhase 3—0———
triletidePhase 2—0———
triptorelinApproved (phase 4)Phase 436November 11, 2026 NCT05050084H. Lee Moffitt Cancer Center and Research Institute, NRG Oncology2000
trofinetideApproved (phase 4)—1June 2027 NCT06705816University of Minnesota2023
trolamine polypeptide oleate condensateApproved (phase 4)—0——1958
ucasareotide dasaroxetanPhase 2—0———
ularitidePhase 3—0———
ulimorelinPhase 3—0———
utreglutidePhase 2—0———
vanutide cridificarPhase 2—0———
vapreotidePhase 3—0———
vasoactive intestinal peptidePhase 3—0———
vasopressinApproved (phase 4)Phase 429October 1, 2026 NCT02118467Hospital do Coracao, Assistance Publique - Hôpitaux de Paris2014
vasopressin tannateApproved (phase 4)—0——1982
veldoreotidePhase 2—0———
vensemaglutidePhase 2—0———
vezocolmitidePhase 2—0———
vicatertidePhase 2—0———
vipivotide tetraxetanApproved (phase 4)Phase 438October 15, 2026 NCT06894511Novartis Pharmaceuticals, University of Washington2022
vipivotide tetraxetan galliumPhase 2Phase 21September 1, 2028 NCT06039371University of Washington—
vipivotide tetraxetan gallium ga-68Phase 2Phase 21September 1, 2028 NCT06039371University of Washington—
vipivotide tetraxetan lutetiumApproved (phase 4)Phase 28December 30, 2026 NCT06145633Jonsson Comprehensive Cancer Center, University of Washington2022
visepegenatidePhase 2—0———
vorumotidePhase 2—0———
vosoritideApproved (phase 4)Phase 313March 2027 NCT06668805BioMarin Pharmaceutical, Andrew Dauber2021
vurolenatidePhase 2—0———
xelafaslatidePhase 2—0———
zelenectidePhase 2Phase 24March 2028 NCT06225596BicycleTx Limited—
zelenectide pevedotinPhase 2Phase 24March 2028 NCT06225596BicycleTx Limited—
zendusortidePhase 2—0———
ziconotideApproved (phase 4)—3September 2027 NCT04321408Christian Hospital Northeast Northwest, ESTEVE Pharmaceuticals SAS2004
zifogaptidePhase 2—0———
zoptarelin doxorubicinPhase 3—0———

Phase is ChEMBL's highest recorded phase for the molecule; the active-study columns come from ClinicalTrials.gov studies that are recruiting, not yet recruiting, active or enrolling by invitation. Method and field definitions: methodology.

← Encyclopedia